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ABSTRACT
The main objective of this dissertation was to gain an
understanding of orexin receptor activation at the molecular
level and apply it in discovery of novel orexin receptor ligands.
As non-peptide orexin receptor activators were almost
completely unknown at the start of this study, attention was
focused on them. To accomplish these goals, I utilized a
combination of molecular modelling and pharmacological in
vitro studies.
First, I studied the known orexin receptor ligands by
structure- and ligand-based computational methods, and
assembled the hypothesized activation features for a
pharmacophore model. The model was utilized in a virtual
screening, and a hit list of 395 compounds continued to a
pharmacological screening phase, wherein I assessed their
activities in a functional Ca2+-based screening assay developed
particularly for that purpose. I validated the screening hits in
the competition binding and Ca2+ elevation assays; six
compounds showed weak agonist activity and Ki’s in the
30 μM range (Publication I). Antagonists with sub-
micromolar binding affinities were also identified.
Retrospective docking simulations of these agonistic hits and
known non-peptide orexin receptor agonists (Nag26 and
Yan7874, the latter of which was pharmacologically
characterized in Publication II) were used to devise a working
hypothesis of the binding pocket regions important for orexin
receptor activation. Interactions in the antagonist binding
region and two additional sub-pockets—one between TM5 and
TM6, and the other approximately one helical turn above the
antagonist binding site close to TM7—would be needed for
orexin receptor activation (Publication I).
Relying on this, I constructed a targeted azulene-based
combinatory compound library accessible to in-house
chemistry. The azulene library was virtually screened at the
crystal structure of OX2 receptor, and compounds selected from
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the hit list were synthesized and screened in vitro. I validated
the hits as above, and novel antagonists, weak agonists and
compounds potentiating the actions of orexin-A were identified
(Publications III and IV).
The literature review focuses on the concept of GPCR




Väitöskirjatyöni tarkoitus oli tutkia
oreksiinireseptoriaktivaatiota molekyylitasolla ja käyttää saatua
tietoa uusien oreksiinireseptoriligandien löytämiseen.
Aloittaessani työtäni oreksiinireseptoreja aktivoivia
pienmolekyylejä ei tunnettu käytännössä lainkaan, joten
keskityin ensisijaisesti niihin. Näihin tavoitteisiin päästäkseni
käytin tietokoneavusteisia menetelmiä synergiassa in
vitro -kokeiden kanssa.
Oreksiinireseptoriligandien tutkiminen rakenne- ja
ligandipohjaisilla tietokoneavusteisilla menetelmillä johti
mahdollisten – reseptoriaktivaation kannalta oleellisten –
vuorovaikutuspisteiden tunnistamiseen ja farmakoforimallien
rakentamiseen. Käytin parasta malleistani virtuaaliseulontaan,
jonka perusteella 395 yhdistettä jatkoi tätä varten
kehittämäämme Ca2+ vapautumiseen perustuvaan in
vitro -seulontaan. Validoin seulontahitit sitoutumis- ja
funktionaalisin kokein; kuusi hittiä osoittautui heikoiksi
oreksiinireseptoriagonisteiksi (Ki:t 1 30 μM; osatyö I). Lisäksi
löysimme oreksiinireseptoriantagonisteja, joiden
sitoutumisaffiniteetit olivat nanomolaarisella tasolla.
Tutkimme yhdisteitämme ja tunnettuja ei-
peptidirakenteisia oreksiinireseptoriagonisteja (Nag26 ja
Yan7874; jälkimmäisen farmakologinen karakterisointi on
esitetty osatyössä II) myös telakoinnin avulla.
Telakointitulokset viittasivat kolmen sitoutumistaskun
tärkeyteen oreksiinireseptoriaktivaation kannalta. Nämä taskut
– antagonistimolekyylien sitoutumispaikka, alue TM5 ja
TM6 -heliksien välissä sekä toinen alue noin yhden helikaalisen
kierteen verran antagonistien sitoutumispaikan yläpuolella
lähellä TM7:ää – vuorovaikuttivat kaikkien tutkittujen
agonistiligandien kanssa (osatyö I).
Suunnittelimme tähän aktivaatiohypoteesiin perustuen
virtuaalisen atsuleeniyhdistekirjaston, jonka synteesi olisi
mahdollista osastollamme. Virtuaaliseuloin kirjaston OX2-
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reseptorin kiderakenteeseen ja seulonnan tuloksista valitut
yhdisteet syntetisoitiin ja testattiin in vitro. Validoin hitit yllä
kuvatulla tavalla ja löysin uusia oreksiinireseptoriantagonisteja,
heikkoja agonisteja ja yhdisteitä, jotka vahvistavat oreksiini-A-
välitteistä reseptoriaktivaatiota (osatyöt III ja IV).
Työni kirjallisuuskatsaus käsittelee G-proteiinikytkentäisten
reseptorien aktivaatiota sekä oreksiinijärjestelmän rakennetta




’The Road goes ever on and on
Down from the door where it began.
Now far ahead the Road has gone,
And I must follow, if I can,
Pursuing it with eager feet,
Until it joins some larger way
Where many paths and errands meet.
And whither then? I cannot say.’
Bilbo Baggins in The Fellowship of the Ring (1954)
I was caught by the Road in 2013, and as Bilbo Baggins, I did
not remain unchanged either. Hereby, I would like to thank all
those people who have accompanied me during this journey.
First, I wish to express my warmest gratitude to my
supervisors Dr. Henri Xhaard and Prof. Jyrki Kukkonen.
Without you there would not be a scientist currently known as
me. Henri, we have walked together for long time, and I would
not change a day (or at least not statistically significant number
of days). I appreciate and admire your scientific curiosity and
the preciseness of your work, and I am grateful that you have
taught me the essence of being a scientist. Oh, and thanks for
the beer in ISB. Jyrki, thanks for believing in my vision also in
those days I did not—your company has delighted me in the
good days and support made me tolerate the rainy ones.
I would like to thank my custos Prof. Jari Yli-Kauhaluoma
for being the most approachable person ever. You inspired me
when I was an undergraduate student and you still do.
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My sincere thanks go to my pre-examinors Prof. Emeritus
Mika Scheinin and Dr. Chris de Graaf. Your positive feedback
really made my day. Thanks for Prof. Risto Kostiainen and
Associate Prof. Vincenzo Cerullo for being the grading
committee of my thesis. Furthermore, I would like to thank my
opponent Associate Prof. Jens Carlsson—I wish we will engage
in brilliant scientific discussion.
 I am grateful to doctoral candidate Teppo Leino and Dr. Erik
Wallén for fruitful collaboration during these years. Teppo, you
have been a peer support beyond belief, thanks for the time in
the various glass boxes. Additionally, I would like to thank Erik
for being a member of my thesis committee.
Prof. Adrian Goldman and Dr. Sarah Harris, thank you
deeply for making my research visit to Leeds both possible and
memorable. Adrian, you made me rediscover that one can
accomplish anything if letting go the mental restrictions (I mean
the ballet dancing obviously). Sarah, you are just most lovely
and inspiring and warmest person ever. The time I spent
working with you gave me a scientific attitude, which carried me
through—among other things—the writing process culminating
in this dissertation.
I am grateful to all my collaborators in mPPase and orexin
projects—Prof. Colin Fishwick, Dr. Roman Tuma, Dr. Gustav
Boije af Gennäs, Dr. Keni Vidilaseris, Dr. Nita Shah, Dr. Craig
Wilkinson, Dr. Steven Harborne, Dr. Alexandros Kiriazis, Mr.
Aaron Wilkinson, and last but definitely not least Mr. Niklas
Johansson. It has been a pleasure.
My deepest gratitude goes to the current and former
members of CDD research group—my extended family. Dr. Leo
Ghemtio, Mr. Lasse Karhu, Ms. Maiju Rinne, Mr. Evgeni
Grazhdankin, Mr. Loïc Dreano, Mr. Ashenafi Legehar, and Mr.
Niccolò Palazzi; you could not have carried the writing process
for me but you have definitely carried me. Also, the former
CDD’ers Dr. Vigneshwari Subramanian, Dr. Alexandre Borrel,
Dr. Gloria Wissel, Dr. Michal Stepniewski, Dr. YueZhou Zhang,
and Dr. Aniket Magarkar thanks for the time you walked with
me.
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I would like to acknowledge my graduate schools ISB and ILS
for social events and generous travel grants. Additionally, I
would like to thank the COST action CM102-GLISTEN for an
active pan-European research network. I am indebted to Jane
and Aatos Erkko foundation and the Academy of Finland for
funding my work with the membrane-bound pyrophosphatases.
Finally, I am sincerely grateful to the Finnish cultural
foundation and Orion research foundation for funding my
orexin research leading to this dissertation.
My warm thanks go to the personnel of the day care centre
Kissankello, especially Merja, Tuula, Tuija and Sari. Without
you, this dissertation could not have existed within this time
frame.
I am grateful to my parents for raising me up by supporting
my strengths and interests. Without the can-do attitude I have
learned from you, I would not have reached this far. Yes, you
have surely done something right (read: Emmää ny silti tiä, mut
kai te ny ootte jotai oikeenki tehny).
Finally, I would like to thank my beloved boys—Mikko, Eero
and Vilho. You are the major reason I have managed to maintain
sanity during this process. Thank you for your unconditional
love. ’Ja kuitenkin / Kuitenkin / Yksi on suurempi muita / Nyt
ja aina / Ja kun sen kohtaa et kysele hintaa / Tai kuuntele
jeesusteluita / Ne ei mitään paina / Ne ei helli ja polta sun
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OR Kappa opioid receptor
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The orexin system, composed of two G protein-coupled
receptors OX1 and OX2 and peptide agonists orexin-A and
orexin-B, is connected to several physiological functions and is
crucial for sleep-wake regulation. Activating orexin receptors
with non-peptide ligands has proven to be challenging;
however, there is a need for a discovery of such compounds for
example to treat narcolepsy. One way to efficiently achieve this
is by understanding orexin receptor activation at molecular
level.
   At the commencement of the studies for this doctoral thesis
in 2013, the knowledge of orexin system was relatively
scattered. At that time, amino acid sequences of orexin
receptors and solution structures of orexin peptides had been
published, and point mutation studies and receptor chimeras
had identified the approximate location of the orthosteric
binding site (Figure 1). Additionally, only one possible non-
peptide orexin receptor agonist, Yan7874, had been reported in
the patent literature, but conversely a variety of orexin receptor
antagonists had been discovered. Thus, we aimed to utilize
computational methods to merge that knowledge and identify
the molecular attributes that lead to orexin receptor binding and
activation. Subsequently, the goal was to apply the gained
understanding and identify novel orexin receptor ligands,
preferably activators.
This dissertation, a joint project between the Division of
Pharmaceutical Chemistry and Technology (Faculty of
Pharmacy) and the Department of Veterinary Biosciences
(Faculty of Veterinary Medicine) of University of Helsinki,
consists of three peer-reviewed publications and a manuscript
(referred as publications I–IV). Publication I presents a
pharmacophore-based virtual screening combined with a
pharmacological screening and validation of the identified hits
(antagonists and weak agonists with sub-micromolar binding
affinities); publication II verifies the agonist activity of the
21
template molecule used in pharmacophore modelling. While
writing these publications, Nag26, the first full non-peptide
orexin receptor agonist, was discovered, and OX2 receptor
crystal structure in complex with small molecule antagonist
suvorexant was reported (Figure 1). Together with our findings,
they opened new insights into orexin receptor activation.
Figure 1. Orexin research timeline. 1998: The orexin system was discovered.
2001: First orexin receptor antagonists were disclosed. 2006: The NMR
structure of full-length orexin-A was solved. 2010: Yan7874 was reported in
a patent literature. 2010–2012: The orthosteric binding site was identified by
point mutations and receptor chimeras. 2013: The studies for this
dissertation started. 2014: Orexin receptor antagonist suvorexant was
approved by FDA for treatment of insomnia. 2015: Nag26 was published.
2015–2018: The crystal structures of orexin receptors in complex with
subtype selective and dual antagonists were solved. 2016: Publication I.
2017: Publication II. 2018: Publications III and IV. The schematic
representations of OX1 and OX2 receptors and corresponding chimeras are
modified from 1.
Inspired by the new data, we constructed a targeted virtual
library of azulene-based compounds accessible to the medicinal
chemistry developed in-house to identify novel orexin receptor
ligands. We conducted a virtual screening at the crystal
Introduction
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structure of OX2 receptor and selected a subset of the hit list
compounds for synthesis. Subsequently, these compounds were
pharmacologically screened and verified, and among these,
orexin receptor antagonists, weak agonists, and compounds
potentiating the actions of the endogenous ligand orexin-A were
identified (publications III and IV).
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2 REVIEW OF THE LITERATURE
2.1 G PROTEIN-COUPLED RECEPTORS
G protein-coupled receptors (GPCRs) are a large receptor family
that are encoded by more than 800 genes in the human genome
(about a half of which have sensory functions).2,3 GPCRs are
embedded in cell membranes throughout the human body,4 and
share a common structure: an extracellular N-terminus, seven
helical transmembrane domains (TM1–TM7) linked by three
extra- and intracellular loops (ECL1–3 and ICL1–3,
respectively), and an intracellular C-terminus.2,3 In general, the
ligand binding on the extracellular side of the receptor triggers
intricate signalling cascades inside the cell, which ultimately
leads to the physiological response. Thus, GPCRs offer a
molecular switch, which can be utilized to regulate a wide
variety of physiological responses, making them attractive drug
targets.3,5 Indeed, the signal transduction modulated by GPCRs
is essential from visual, olfactory, and gustatory sensation to
neurological, cardiovascular, endocrine, and reproductive
functions.
2.1.1 PHARMACOLOGICAL MODULATION OF GPCRS
Human GPCRs are divided into five main families based on
their sequence similarity: Rhodopsin (class A), Secretin and
Adhesion (class B), Glutamate (class C), Frizzled (class F) and
Taste 2 (class T).3,6–9 Of these, the Rhodopsin-family is both the
largest and most thoroughly studied, and many endogenous
ligands are known.3 GPCR-targeted drug design has mainly
focused on the Rhodopsin-family, and consequently,
approximately 30% of the drugs in the market act via these
GPCRs.5,10
Apart from the GPCR ligands found in nature (e.g. μ opioid
receptor agonist morphine, reviewed in 11), GPCRs have been
originally targeted by compounds mimicking the endogenous
Review of the literature
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ligands either to achieve a similar physiological response (e.g.
salbutamol, which activates the 2-adrenoceptors in the lungs
for the treatment of asthma), or to block the physiological
response by competing with the endogenous ligand (e.g.
propranolol, which blocks the response to noradrenalin via -
adrenoceptors in the treatment of hypertension, see e.g. 12).
Currently, GPCR-targeting ligands are typically classified as
agonists (triggers a similar response to the endogenous ligand),
neutral antagonists (blocks the response to the endogenous
ligand without affecting the basal activity of the receptor), or
inverse agonists (as antagonist, but reduces also the basal
activity; reviewed in 13,14). Furthermore, ligands can act as
partial agonists; the maximal response to a partial agonist is
only a fraction of the maximal response to the endogenous
agonist. Finally, a biased agonist stabilizes a certain receptor
conformation resulting in the activation of one signalling
pathway over another.15
In addition to the classical agonists and antagonists acting
via an orthosteric binding site (i.e. the binding site of
endogenous ligand), GPCRs can be regulated with ligands
targeting other binding sites.5 Allosteric ligands are compounds,
which act at a site that is topographically different from the
orthosteric binding site, and thus modulate the actions of the
endogenous ligand making it more or less potent (positive and
negative allosteric modulators, respectively; reviewed in 14).
Furthermore, positive allosteric modulators can have some
agonist activity of their own (ago-allosteric ligands, reviewed in
16). Bitopic ligands can act simultaneously at both orthosteric
and allosteric binding sites (reviewed in 17). Bivalent ligands,
instead, can bridge a dimeric construct of GPCRs and bind
simultaneously at the binding sites of adjacent receptors
(reviewed in 18).
2.1.2 G PROTEIN SIGNALLING CYCLE
GPCRs signal via heterotrimeric G proteins, which are
composed of -, -, and -subunits (reviewed e.g. in 19–23; Figure
25
2). These subunits—and -subunit-bound GDP—remain in
complex while the G protein is in the resting state. Activation of
the receptor drives the release of GDP and the binding of GTP,
which triggers a conformational change in G protein structure.
Typically, the conformational change leads to the dissociation of
the complex to separate - and -subunits (G  and G ,
respectively), which then interact with their downstream
effectors. However, the complex does not necessarily fully
dissociate in the downstream signalling (reviewed in 24).
G proteins are divided into four families based on their G
subunits: Gi,  Gs,  Gq,  and  G12/13 (reviewed in 25). In much
simplified terms, G s and G i activate and inhibit adenylyl
cyclase (AC), respectively, which leads to the alteration of the
levels of the secondary messenger cAMP, and thus the functions
of e.g. protein kinase A (PKA; reviewed in 26,27). G q stimulates
phospholipase C (PLC), which hydrolyses inositol
phospholipids (e.g. phosphatidylinositol-4,5-bisphosphate
a.k.a. PIP2) into diacylglycerol (DAG) and inositol phosphates,
such as inositol trisphosphate (IP3, reviewed in 28–30). DAG and
IP3 are second messengers, which activate protein kinase C
(PKC) and Ca2+ release from endoplasmic reticulum (ER),
respectively. PLC also affects functions of other membrane
proteins such as ion channels via regulation of the membrane
levels of inositol phospholipids. G 12/13 has mainly reported to
activate Rho guanine nucleotide exchange factors (RhoGEFs;
reviewed in 26), which leads to various effects, such as the
regulation of Na+/H+ exchanger. Apart from G s, G  subunit
can participate in signalling cascades of its own, for example,
targeting some PLC isoforms and K+ and Ca2+ channels
(reviewed in 23,27,30).
 At the end of the G protein signalling cycle, the G protein
returns to its resting state upon a hydrolysis of GTP to GDP by
the G -subunit. The hydrolysis can be enhanced by regulator of
G protein signalling proteins (RGS proteins; reviewed in 20,23,27).
Apart from the built-in catalytic activity of G , there are also
other mechanisms to dampen any prolonged signalling, such as
GPCR kinase (GRK) -catalysed receptor phosphorylation, which
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then recruits intracellular regulatory proteins -arrestins
(reviewed in 23,27,31; Figure 2). -arrestins have intricate roles in
cellular processes leading, for example, to G protein uncoupling,
receptor internalization, and intracellular trafficking (recycling
or degradation). Additionally, similar to G protein-GPCR–
complexes, -arrestin–GPCR complexes have signalling
pathways of their own (reviewed in 27,31).
Figure 2.A schematic representation of the G protein cycle. In the resting
state, the GDP-bound heterotrimeric G protein consists of , , and 
subunits (orange). Agonist (blue) and G protein binding to the GPCR leads
to GDP release. The trimeric G protein complex remains stable until the GTP
binding causes dissociation of G -GTP and G  subunits. Subsequently, the
subunits activate downstream effector proteins, such as adenylyl cyclase
(AC) or G protein-coupled inwardly rectifying potassium channels (GIRKs).
The signalling terminates by hydrolysis of GTP to GDP and reassociation of
the G protein. Receptor activation can also lead to GRK-mediated receptor
phosphorylation and, subsequently, coupling to -arrestin (GRK in red;
inactive -arrestin in green; active -arrestin in teal). Arrestin binding leads
to desensitization and activation of several downstream effectors, such as
mitogen-activated protein kinases (MAPKs). Additionally, -arrestin
activation promotes receptor internalization leading to receptor degradation
or recycling. Adapted from 23 by permission from Springer Nature (Copyright
2018).
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2.1.3 ACTIVE AND INACTIVE GPCR CONFORMATIONS
GPCR structures can oscillate among different conformational
states, which can be represented as an equilibrium between
each other (the states R, R’, R’’, R*, or R*G are presented in
Figure 3). Additionally, current functional, structural,
spectroscopic, and computational data suggest that the ability
of GPCRs to regulate a variety of signalling pathways originates
from the allosteric coupling between the orthosteric binding site
and the intracellular G protein/ -arrestin-binding site
(reviewed in 23). How these dynamic conformational states are
associated with the functional outcomes, and how they are
regulated by different ligands remains not fully understood.
Figure 3. A schematic representation of GPCR structure, and structural
changes upon receptor activation. R means the inactive state, and R’ the
inactive low-affinity agonist-bound state differing from R only by small local
changes of the binding pocket side chains. R´´ is the activated state
(rearrangement of helices and side chain microswitches). R  represents
activated sub-states co-crystallized with the G protein C-terminal -helix (or
its mimic; g) in the intracellular G protein-binding cavity. R G is the distinct G
protein signalling conformation of the receptor, achieved upon full
engagement and activation of the GPCR–G -complex. Other, not-
presented, states include GPCR binding to G protein receptor kinases
(R GRK) and to -arrestin (R A). Adapted from 32 by permission from Annual
Reviews Inc (Copyright 2013).
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Within the last decade, GPCRs have been successfully
studied by biophysical methods, such as x-ray crystallography,
and the active–inactive receptor pairs have provided insights
into the conformational changes occurring during receptor
activation (Figure 3; reviewed in 32,33). Currently, the structures
of rhodopsin, 1- and 2-adrenoceptors ( 1 and 2), A2 adenosine
(A2A), M2 muscarinic acetylcholine (M2), μ opioid (μOR),
angiotensin 2 (AT2), and endothelin B (ETB) receptors have
been solved in both inactive (antagonist-bound or ligand free
apo form) and different forms of active conformations (for
rhodopsin, 1, 2, and A2A see Table 2 in 32, for M2 and μOR see
33–35, for  AT2 see 36, and for ETB see 37). Additionally, the
agonist-bound structures of neurotensin 1 (NTS1)38, and 5-HT1A
and 5-HT1B serotonin receptors (5-HT1A and 5-HT1B)39 are
reported, however the antagonist-bound or apo forms of these
remain currently unsolved.
Of the structures of the active receptors, only 2 is solved as
a fully active G protein-bound state,40 and additionally
rhodopsin-receptor structures in complex with C-terminal
peptide of G  representing the active receptor conformations
are reported (reviewed in 32; R* and R*G states in Figure 3).
When comparing the active 2 to the corresponding inactive
conformation, the most significant structural changes are
observed within the intracellular domains of TM5 and TM6:
TM5 is extended by two helical turns whereas TM6 is moved
outward by 14 Å (the distance between -carbons of Glu6.30 of
the two structures).40 Additionally, ICL2, TM5 and TM6 are in
the direct contact with the G protein.40
The amino-acid sequences of the Rhodopsin-family GPCRs
share several characteristics such as D[E]RY motif at the border
between TM3 and ICL2, CWxP motif in the vicinity of the
orthosteric binding site in TM6, and NPxxY motif in TM7 (2,6,
reviewed in 32). In the inactive GPCR structures, the salt bridge
between Arg3.50-Asp3.49 in the DRY motif of TM3 is highly
conserved (reviewed in 32; Table 1). In the aforementioned
active-state structures of rhodopsin and 2 instead, the Arg3.50-
Asp3.49 salt bridge is broken and the arginine residue interacts
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with Tyr5.58 and the G protein. The Arg3.50-Tyr5.58 interaction is
also present in the peptide-agonist-bound NTS1 structure.38
However, Arg3.50-Asp3.49 salt bridge is intact in NTS1, as in the
all active GPCR structures solved in absence of the G
protein(mimic) (reviewed in 32).
In the inactive structures of rhodopsin and 2 also another
salt bridge, so called ‘ionic lock’, between Arg3.50-Glu6.30 is
observed (Table 1; reviewed in 41). The ionic lock stabilizes these
inactive receptor conformations and breaks during the receptor
activation. However, the role of ionic lock within the full
receptor family is possibly less prominent, as the acidic residue
in location 6.30 is conserved only among 30% of GPCRs
(reviewed in 32).
  As only the 2 and rhodopsin receptors are solved in the
fully active conformations, the most of the active GPCR
structures represent the pre-activated state of the receptor (i.e.
their structures are solved in complex with agonist ligands but
in absence of the G protein or its mimic; R’’ in Figure 3). These
structures lack the most prominent conformational changes of
receptor activation, however, they have allowed the
identification of more subtle structural rearrangements,
referred as microswitches (reviewed in 32). The microswitches
are considered to be subsequently connected to the larger
conformational changes in the locations of TM helices,
especially those of TMs 5 and 6 (Table 1; for orexin receptors,
see Figure 5).
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Table 1. Structural changes between active and inactive GPCRs.32–34,36,37,42
The residue conservation is given as a percentage within the Rhodopsin-
family GPCRs (as in 32). The changes are presented in the order based on































































The first set of these conformational changes could occur
close to the ligand binding site, where Trp6.48 (from conserved
CWxP motif) can interact directly with the bound agonist
leading to movement of TM6 (reviewed in 32). However, for 2,
for example, the conformation of Trp6.48 is stabilized by inverse
agonists and thus it is unlikely connected to the receptor
activation. In the case of 2, triggering the movement of the
TM5–TM6 region is supposed to be connected with the
interactions of the bound agonist and residues Ser5.42 and
Ser5.46.43 Additionally, in 2, the agonists form tight hydrogen
bonding interactions with Asp3.32 in TM3 and Asn7.39 in TM7,
which could affect the conformational changes of the
microswitch amino acids further away from the ligand binding
site (reviewed in 32). Notably, in the aminergic and opioid
receptors, the acidic side chain Asp3.32 is fully conserved and a
critical interaction point for ligand binding and receptor
activation. Of the peptide binding GPCRs, such as endothelin 1
(ET1), the activating peptide ligand of endothelin receptors, can
interact with Gln3.32 and Trp6.48 in the ETB crystal structure.37
The ligand binding interactions could then drive the changes
in the location of the amino acid triad Pro5.50–Ile3.40–Phe6.44
(Table 1). It is suggested that the movement of TM5 switches the
conformation of Ile3.40, which in turn moves Phe6.44 and swings
the intracellular domain of TM6 (34, reviewed in 32).
Interestingly, Ile3.40 is two helical turns below Asp3.32, and in
μOR their movements seem to be strongly coupled.34
In the structures of inactive GPCRs TM6 is in contact with
TM3; this contact is detected as a shortest distance between the
amino acid residues in locations 3.46 and 6.37, and it is
conserved within the inactive GPCR conformations (Table 1).33
In the active conformations, TM3 interacts with TM7 instead,
with the contact point being amino acid 3.46 and the conserved
Tyr7.53 of the NPxxY motif in TM7 (Table 1).33 Additionally, a
water-mediated hydrogen bond involving Tyr7.53 and Tyr5.58
from TM5 is observed in many active GPCR structures, and it is
suggested to stabilise the active receptor conformation (Table 1;
reviewed in 32). In the inactive conformations, Tyr7.53 is  in
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contact with TM1 and helix 8 (locations 1.53 and 8.50,
respectively).33
2.2 THE OREXIN SYSTEM
2.2.1 OVERVIEW
In 1998, two research groups reported individual findings
regarding the orexin (hypocretin) system: de Lecea et al.
identified messenger RNA (mRNA), which encoded the
precursor of two peptides selectively expressed in
hypothalamus;44 while Sakurai et al. reported their findings of
two hypothalamic neuropeptides activating two closely related
orphan GPCRs.45 The currently established orexin system
comprises these two GPCRs, OX1 and OX2 receptors (OX1 and
OX2, respectively), and the neuropeptide agonists orexin-A and
orexin-B (naming according to 2).44,45
2.2.2 OREXIN PEPTIDES
The human neuropeptides, orexin-A and orexin-B, are cleavage
products of a single 131 residue precursor prepro-orexin.45
Orexin-A is a 33 residue peptide with two disulphide bridges
(Cys6–Cys12, Cys7–Cys14) in the N-terminal, whereas orexin-B
is a linear 28 residue peptide (residues 33–66 and 69–97 of the
prepro-orexin, respectively; Figure 4A). The C-terminal ends of
these peptides are highly similar, including an amidated C-
terminus, while the N-terminal ends show more variation.
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Figure 4. A. Sequence alignment of the amino acid sequences of human
orexin-A and orexin-B. B. Examples of the NMR structures of bent and
straight orexin-A conformations (PDB ID: 1WSO).46 Disulphide bridges are
shown as sticks (carbon: light blue, sulphur: yellow) C. The NMR structure of
orexin-B (PDB ID: 1CQ0).47 In B and C the N-terminal of the peptides are up
and C-terminal down.
 The NMR-structures of orexin peptides have been solved in
water-based buffers. Orexin-A has three helical parts and its C
terminal end adopts either straight or bent conformation in
aqueous solution (Figure 4B).46 Orexin-B, instead, consists of
two helical regions, for which only one conformation is reported
(Figure 4C).47 The importance of the amino acids in orexin
peptides have been thoroughly studied, and the C-terminal end,
including the amidation, has been shown to be the key for the
activity of these peptides.48–52
The native orexin peptides are equipotent towards OX2
receptors, when studied in recombinant CHO cells.48,52 Orexin-
A has equal efficacy and potency also towards OX1 receptors,
Review of the literature
34
whereas orexin-B prefers OX2 receptors by approximately 10-
fold. The C-terminal fragment of orexin-A retaining nanomolar
binding affinity for OX1 receptors is 19 amino acids long,
whereas the orexin-A truncates in lengths of 19 to 12 amino
acids have been reported to retain some functional activity. 48,50–
53 For orexin-B, instead,  the shortest C-terminal fragment
binding to orexin receptors is 15 amino acids long.52 Especially
the C-terminal amino acids 29–33, and Arg15, Tyr17, Leu20,
Asn25, and His26 have shown to contribute the functional
activity of orexin-A.48,50,51 Whether the C-terminus of orexin-A
is required in helical conformation for bioactivity is currently
unknown, however a recent study by Karhu et al. provides
evidence that orexin receptors can be activated by permanently
-helical peptides.53 Unlike the C-terminus, no crucial amino
acids have been identified in the N-termini of orexin
peptides.48–52
2.2.3 OREXIN RECEPTORS
Human orexin receptors, OX1 and OX2, are composed of 425 and
444 amino acids, respectively, and they are encoded by the
genes HCRTR1 and HCRTR2, respectively.45 As GPCRs, the
structures of orexin receptors consist of seven transmembrane
helices and three intra- and extracellular loops, as shown by
their recently reported three-dimensional structures (PDB IDs:
4ZJ8, 4ZJC, 4S0V, 5WQC, and 5WS3; Figure 5).54–56 OX1 and
OX2 share a 64% full-length pairwise sequence identity, and if
the termini and ICL3 are excluded, the identity rises up to 80%.
All currently reported orexin receptor crystal structures are
solved in complex with small molecular antagonists, and thus
they represent an inactive receptor conformation (Figure 5; see
also Figure 3). Phylogenetically, orexin receptors belong to the
-branch of the Rhodopsin family, together with other peptide-
binding GPCRs, such as neurotensin and endothelin receptors.6
Prior to the determination of the orexin receptor crystal
structures, the ligand binding site of orexin receptors had been
identified by point mutations and receptor chimeras.1,54,57–60
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These studies showed that the orthosteric orexin-A binding site
of both orexin receptors is identically located in between the
TMs3–7 and involve also amino acids from ECL2 (Figure 5, grey
surface). In more detail, amino acids Gln3.32, Val3.36, Aspxl2.51,
Trpxl2.45, Tyr5.38, Phe5.42, Tyr6.48, Asn6.55, His7.39, and Tyr7.43 are
shown to clearly contribute to the response to orexin-A on OX1,
and thus they were expected to be located on the orthosteric
binding site (for the nomenclature, see 61,62).54,57 On OX2, these
and also Thr5.46 have a role in the potency of orexin-A.58 When
considering orexin receptor antagonists almorexant, SB-
674042 and EMPA (see chapter 2.5.1), instead, amino acids
Thr2.61 (on OX2 only), Ala/Thr3.33, Gln4.60, Tyr5.47, and Ile6.51, in
addition to those listed above, impart to the binding of these
ligands.57,58,60 These findings of the location of the orthosteric
binding site were later confirmed by the crystal structures.
Apart from the ligand binding site, the orexin receptor
crystal structures offer insights into the overall receptor
conformation. One interesting observation is the amphipathic
-helix formed by the N-terminal amino acids Glu1.14–Arg1.23,
which is suggested to contribute to the binding/recognition of
orexin-A.54 Deletion of that -helix led to receptor constructs
with no activation by orexin-A (up to 1 μM concentration), and
asparagine mutations on the lipophilic phase of the helix lead to
a similar outcome. The N-terminal -helix is observed in both
OX1 and OX2 (for OX2, see Figure 5);54,56 in OX1 crystal
structures it interacts with the -hairpin structure of the ECL2,
whereas in OX2 it points in the opposite direction. In addition
to the orexin receptors, the -hairpin is present in the structures
of other peptide-activated GPCRs such as CXCR4 chemokine
receptor (CXCR4)63, opioid receptors34,64–66, NTS1 neurotensin
receptor (NTS1)38, endothelin B receptor (ETB)37, and
angiotensin receptors (AT1 and AT2)36. In case of orexin
receptors, the mutation of Aspxl2.51, located in the -hairpin, to
alanine has a large effect on the efficacy of orexin-A illustrating
the importance of this region.57
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Figure 5. Structural indicators of GPCR activation presented on OX2 crystal
structure (pdb ID: 5WS3). The receptor is shown as cobalt blue cartoon, and
amino acid residues as white sticks (carbon). Red is for oxygen, blue for
nitrogen and yellow for sulphur. Green dashes represent possible hydrogen
bonds and the grey surface the ligand binding pocket. The black horizontal
lines indicate the approximate location of the cell membrane (determined by
hydrophobic surface of the receptor). Parts of TM6 and TM7 helices are
hidden for clarity.
Another feature involving -hairpin is highly conserved
disulfide bridge between it and the top of TM3 (Cys3.25; reviewed
in 67). In orexin receptors, this bridge is observed between
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Cysxl2.50 and Cys3.25.54,55 Considering the other conserved motifs
of Rhodopsin-family GPCRs (see chapter 2.1.3), only NPxxY in
TM7 is fully conserved in the structures of orexin receptors
(Figure 5).54–56 In CWxP in TM6, there is Tyr6.48 instead of
Trp6.48 in the orexin receptor structures, V3.40 instead of I3.40 in
P5.50–I3.40–F6.44 –triad, and Trp3.51 instead Tyr3.51 in the DRY
motif of TM3. Additionally, in orexin receptors, R6.30 replaces
Glu6.30, and thus ionic lock does not exist.
Allosteric Na+ binding site is commonly observed in the
inactive structures of Rhodopsin-family GPCRs, and it collapses
during receptor activation due to the conformational
rearrangements (reviewed in 42). This binding site is located in
the middle of the TM bundle close to conserved Asp2.50 (95%
conservation among these GPCRs), and involves amino acid
residues in TMs 1, 2, 3, 6, and 7 (Figure 5). It is thus also
connected to the conserved regions CWxP and NPxxY.
Interestingly, Na+ is not observed in the high resolution crystal
structure of OX2, and OX2 function been shown to be Na+-
independent.56 Asp2.50, though, is also conserved in orexin
receptors (Figure 5). Apart from OX2, only the structures of
visual opsins have been reported to lack the allosteric Na+.42
Helix 8 is located to the C-terminal end of orexin receptors
in parallel to the cell membrane, as commonly observed in
inactive GPCR structures (for OX2, see Figure 5). The location
of helix 8 has not been observed to change within the active
GPCR conformations either (e.g. in 37,40), except for the active-
state-mimicking AT2 structure.36 Furthermore, the  CXCR4
structure lacks helix 8.63 Helix 8 is suggested to be involved in
GPCR dimerization (as shown by the structure of  opioid
receptor68). Apart from helix 8, the C-terminal ends  and ICLs2–
3 of both orexin receptor subtypes have several putative
phosphorylation sites (reviewed in 69); point mutations of a
cluster of C-terminal serine and threonine residues (within
amino acids 418–422 in OX1) suggest that they have a role in -
arrestin binding.70
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2.3 OREXIN SIGNALLING
2.3.1 OREXIN RECEPTOR-MEDIATED SIGNALLING
CASCADES
Early on after their discovery, orexin receptors were reported to
couple to Ca2+ elevation and phospholipase C (PLC) in
recombinant CHO cells.45,71–73 Thus, they were considered to
couple with the Gq pathway in their actions (G q PLC  IP3
IP3 receptor Ca2+ release from the ER, see Figure 6), and
induce the cell responses via Ca2+ and DAG-mediated pathways,
such as those resulting from PKC activity. This was soon found
to be too simplistic (see e.g. 74–77), however, the involvement of
the G q pathway in many orexin receptor-mediated responses
in recombinant CHO cells is verified.78
In addition to the PLC pathway, orexin receptors are shown
to regulate AC activity in recombinant CHO cells via both G s
and G i, while regulation of the phospholipase A2 and
phospholipase D cascades (PLA2 and PLD, respectively) may
rely on Gq.74–77 Apart from CHO cells, orexin functions have
been studied in HEK293 and recombinant neuron-like cells, in
which the coupling to Ca2+ elevation and PLC is also shown
(reviewed in 28,79).
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Figure 6. A simplified scheme of G protein pathways coupled by orexin
receptors (as reviewed in 29,30,80,81).  Gs activates and Gi inhibits adenylyl
cyclase (AC), which regulate cAMP levels and protein kinase A (PKA)
activity. Gq activates phospholipase C (PLC) leading to production of
diacylglycerol (DAG) and inositol trisphosphate (IP3) from
phosphatidylinositol-4,5-bisphosphate (PIP2). IP3 binds to IP3 receptor (IP3R)
opening ion channels and releasing calcium ions (Ca2+) from the
endoplasmic reticulum (ER). DAG activates protein kinase C (PKC); PKC,
PLC, PIP2, and Ca2+ release from ER regulate ion channels/exchangers in
the cell membrane leading to a Ca2+ influx.
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2.3.1.1 Phospholipase C (PLC)
Phospholipase C (PLC) is a family of cytosolic phosphoinositide-
specific enzymes (reviewed in 82). The PLC family is divided into
six subfamilies ( , , , , , and ), which share the requirement
of Ca2+ for activation. The most commonly studied substrate of
PLCs is PIP2, but they also hydrolyse other phosphoinositides,
such as phosphatidylinositol and phosphatidylinositol-4-
phosphate/phosphatidylinositol-5-phosphate (reviewed in 29).
Hydrolysis yields DAG and inositol phosphates (in case of PIP2,
IP3), which act as secondary messengers. Additionally, PIP2 can
directly regulate several ion channels (such as voltage-gated
Ca2+ channels [VGCC] and transient receptor potential [TRP]
channels; reviewed in 83,84).
 In general, GPCRs can regulate multiple PLC isoforms, the
most classical being PLC  (via G q family members and G ;
reviewed in 29). Direct measurements of PLC activity in
recombinant expression systems indicate that both OX1 and
OX2 activate PLC (see 2.3.1 above). In native orexin receptor-
expressing cells, PLC activation has been directly shown in
human adrenal gland tumours, and membrane preparations of
human reproductive tract, rat adrenal cortex, and
hypothalamus (reviewed in 29).
2.3.1.2 Protein kinase C (PKC)
PLC activation leads to production of DAG and phosphatidic
acid (PA), which are important lipid second messengers with
many targets (reviewed in 30). Of these, orexin receptor-
mediated DAG release activates, for example, classical (cPKC)
and novel (nPKC) PKCs (reviewed in 85). Upon orexin receptor
activation in recombinant cell systems, these PKCs have been
reported to regulate non-selective cation channels (NSCCs), L-
and N-type voltage-gated Ca2+ channels, inwardly rectifying K+
channels (assessed in neuronal preparations), and PLD and
protein kinases, such as extracellular signal-regulated kinases 1
and 2 (ERK1/2).77,86–89
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2.3.1.3 Adenylyl cyclase (AC)
Apart from PLC, orexin receptors have been shown to regulate
the activity of adenylyl cyclase (AC).76,90–94 Nine plasma
membrane-bound and one cytosolic AC isoforms have been
reported (reviewed in 95). Depending on the isoform, ACs are
regulated by a variety of signals; the common regulator is G s
(activation), but other positive or negative regulators also have
an impact on ACs (such as G i, G , Ca2+ or PKC). Some of the
orexin receptor-mediated AC regulation may relate to the ability
of orexin receptors to couple to Gs proteins (reviewed in 79), but
the contribution of the other cascades, such as Ca2+ and
PLC PKC, cannot be ruled out. The physiological relevance of
AC stimulation by orexin receptors is mostly studied in
adrenocortical cells (in vitro and in vivo), and AC–PKA
activation leads to glucocorticoid synthesis or release from the
adrenal cortex (reviewed in 79).
2.3.1.4 Effects of Ca2+ on orexin receptor signalling
PLC activation also generates IP3, which releases Ca2+ from the
ER into the cytosol via IP3 receptor channels (Figure 6, reviewed
in 81). Subsequently, Ca2+ depletion of ER signals to the plasma
membrane to allow so-called store-operated Ca2+ influx (often
via the plasma membrane Ca2+ channel orai1). Apart from this,
Ca2+ influx can occur via other plasma membrane channels,
such as VGCCs, NSCCs of the TRP family, or Na+/Ca2+(-K+)
exchangers (NCX, NCKX), which pump in Ca2+ at the expense
of Na+ (reviewed in 96). Of these, NSCCs and TRPCs have been
shown to contribute to orexin receptor-mediated Ca2+ influx in
recombinant cell lines, whereas the involvement of VGCCs are
reported in neurons (reviewed in 29,79).
Altogether, a great extent of orexin signalling is connected
with the regulation of intracellular Ca2+ levels, but reciprocally,
these Ca2+ levels also have an effect on downstream orexin
signalling. In CHO-hOX1 cells, the effects of orexin-A to a
number of intracellular pathways, such as PLC, AC, and PLD,
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are strongly dependent on the intracellular Ca2+ concentration
(studied by altering the extracellular Ca2+ concentration or
inhibiting the receptor-operated Ca2+ channels).77,86,97–100 These
pathways are not stimulated by Ca2+ influx alone, but the Ca2+
influx  in synergy with orexin-A, suggesting that the effect of
Ca2+ takes place at the proximal level of orexin receptor
signalling (e.g. receptor–G protein interaction). However, it is
also possible that Ca2+ binds directly to signalling cascade
components, such as PLC, and stimulates the orexin responses.
Apart from the signal transduction machinery,  extracellular
Ca2+ levels affect the binding of orexin-A to OX1 receptors.97
Reducing the extracellular Ca2+ concentration significantly
inhibits the binding of [125I]-orexin-A to OX1 (when studied in
CHO-cells) in a concentration-dependent manner. However,
the blockade of the orexin receptor-mediated Ca2+ influx (to
separate the effects of intra- and extracellular Ca2+) suggests
that Ca2+ levels affect PLC activity, not only via the stimulated
orexin-A binding but also directly via the intracellular signalling
machinery. It is possible that OX1 structure has a regulatory
extracellular Ca2+ binding site, occupancy of which enhances
orexin-A binding, or that Ca2+ acts through receptor dimers (see
below) regulating the ligand binding and/or response to
orexin-A.
2.3.2 OREXIN RECEPTOR DIMERIZATION AND
OLIGOMERIZATION
Numerous studies propose the formation of homodimers,
heterodimers, and higher oligomers of GPCRs (reviewed in
101,102). GPCR dimerization or oligomerization can alter the
pharmacology, function, or regulation of the receptors, and is of
increasing importance for the development of future drug
treatments. In the case of orexins, the formation of receptor
dimers/oligomers has been studied in recombinant CHO and
HEK293 cells.64,103–110 Apart from the homomers and
heteromers between orexin receptor subtypes, OX1 receptors
have been reported to dimerize with CB1 cannabinoid receptors,
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 opioid receptors ( OR), GPR103 receptors, and a complex of
CRF1 corticotrophin-releasing factor receptor and sigma 1
receptor ( 1; not a GPCR). Of these, the complexation of OX1
with OR, GPR103, or CRF1 1 alters efficiently the cellular
responses of these receptors.64,108–110 OX1–CB1 complexation is
also reported to occur,104,106 however the OX1–CB1 synergy is not
necessarily structural, but rather functional, as orexin receptor
activation releases 2-arachidonoylglycerol (2-AG), a CB1
receptor agonist, which could then cause the synergistic
functions of these receptors by CB1 receptor activation.75,107
2.3.3 OREXIN RECEPTOR-MEDIATED CELL DEATH
One way to classify cell death is according to particular
morphological and molecular signatures, wherein the two main
classes are apoptosis and necrosis (reviewed in 111). The main
markers of apoptotic cell death are fragmentation and
condensation of the cells and nuclei, DNA laddering, loss of
plasma membrane polarity, caspase activation, and
mitochondrial membrane permeabilization. The markers of
necrosis, instead, are swelling of the organelles, loss of plasma
membrane integrity, and inflammation. Apoptosis is often used
as a synonym for programmed cell death, whereas necrosis has
been thought to be an uncontrolled form of cell death. However,
the accumulating evidence indicates that necrosis can also have
programmed characteristics and the physiological
‘programmed’ cell death non-apoptotic features (reviewed in
111,112).
Prolonged orexin receptor stimulation has shown to induce
programmed cell death in recombinant CHO cells, as well as in
native cancer cell lines of colon carcinoma, neuroblastoma, and
pancreatic acinar tumour.113–116 Both orexin receptor subtypes
are capable of activating programmed cell death.114,117 In CHO
cells expressing human OX1, two cell-death pathways have been
suggested. The first involves the phosphorylation of a tyrosine
residue of the immunoreceptor tyrosine-based switch motif
(ITSM) of OX1 leading to apoptosis, whereas  the second
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identifies p38 MAP kinase (p38 MAPK) as a carrier of both
caspase-dependent and independent cell death.113,115
2.4 THERAPEUTIC OPPORTUNITIES FOR
TARGETING THE OREXIN SYSTEM
2.4.1 ANATOMY OF THE OREXIN SYSTEM
Orexin peptides are produced by orexinergic neurons in the
brain located within the lateral and posterior hypothalamus (LH
and PH, respectively), and the perifornical area (PF).44,45,118
Humans are estimated to carry approximately 70 000
orexinergic neurons, which send projections to several brain
regions (Figure 7).118–121 Orexin receptor subtypes have been
suggested to have different, but partially overlapping,
expression patterns. The mRNA of both orexin receptors is
found, for example, in the laterodorsal tegmental nucleus
(LDT), ventral tegmental area (VTA), pedunculopontine
nucleus (PPT), and dorsal raphe (DR), whereas mainly OX1
mRNA is found in the locus coeruleus (LC), and only OX2 in the
tuberomammillary nucleus (TMN).118–121 These brain areas are
involved in the regulation of arousal, but they are connected
also, for example, to reward and mood (see below).
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Figure 7. Expression and distribution of the orexins and orexin receptors
involved in arousal and reward in the human brain. LDT: laterodorsal
tegmental nucleus, VTA: ventral tegmental area, PPT: pedunculopontine
nucleus, DR: raphe nucleus, LC: locus coeruleus, TMN: tuberomammillary
nucleus, NAc: nucleus accumbens. The neurotransmitters in each nuclei:
acetylcholine (Ach), noradrenaline (NE), serotonin (5-HT), dopamine (DA),
and histamine (HA). Adapted with permission from 122. Copyright 2016
American Chemical Society.
Orexinergic functions, as well as the presence of the mRNA
of prepro-orexin and of orexin receptors, have been reported in
several organs in periphery (reviewed in 69,123). These organs
include the gastrointestinal tract, pituitary gland, adrenal gland,
pancreas, male reproductive system, and adipose tissue;
however, the physiological significance of peripheral orexins
remain mostly unknown. Interestingly, human neuroblastoma
and colon carcinoma cells, but not healthy colon epithelium,
express OX1 receptors, and the exposure of these to orexins
induces programmed cell death (see 2.3.3).114,116
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2.4.2 SLEEP/WAKE REGULATION
The orexin neurons of the hypothalamus project to cholinergic
and monoaminergic nuclei, which excite the wake-promoting
cerebral cortex (Figure 7). The orexin system is thus essential
for regulating arousal, and it is especially important for
maintaining long periods of wakefulness (44,45 reviewed in 124).
In rodent models, the activity of orexinergic neurons and
extracellular levels of orexin-A are high during periods of high
locomotor activity, and orexin-A injection (i.c.v.) increases
wakefulness and suppresses rapid eye movement (REM) and
non-rapid eye movement (NREM) sleep.121,125,126 Furthermore,
blocking the functions of the orexin system (by orexin receptor
antagonists) induces sleep in mice, rats, dogs, non-human
primates, and humans, which indicates that the main function
of orexin system is indeed wake-promotion.127
The excitatory functions of the orexin system attracted
attention to the possibility that the orexin system could have a
role in the origin of narcolepsy. Type I narcolepsy (i.e.
narcolepsy with cataplexy) is a sleep disorder with chronic,
often severe sleepiness, dysregulated REM sleep, and cataplexy
attacks.128 Orexin knock-out animals show narcoleptic
symptoms, which can be suppressed by administration of
orexin-A, [Ala11]orexin-B, or the non-peptide orexin receptor
agonist YNT-185 (see also chapter 2.5.2.2).129–134 Additionally,
human type I narcolepsy is associated with the loss of
orexinergic neurons and correlates with low levels of orexin
peptides.135,136 Together these results indicate that narcolepsy is
caused by a selective loss of the orexin neurons, but not the
orexin receptors, and thus narcolepsy provides an attractive
target for orexin receptor activators.
On the other hand, blockade of the arousal effects of the
orexin system offers a mechanism to promote sleep, which
could have advantages over the current standard
pharmacotherapies. The commonly used hypnotics, such as
zolpidem, zaleplon, zopiclone, and eszopiclone, act via positive
allosteric modulation of GABAA receptors, which drives sleep
through  inhibitory ligand-gated chloride channels and CNS
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depression (reviewed in 137,138). In principle, this is a nonspecific
and broadly acting approach; apart from the brain regions
responsible for arousal, GABAA receptors are expressed
throughout CNS functioning in a number of pathways.
Targeting orexin receptors is thus a more specific way to
promote sleep compared to the GABAA modulators, and
currently numerous orexin receptor antagonists have been
developed for insomnia treatment. The effects of these are
discussed in more detail under chapter 2.5.1.
The differences in the orexin receptor subtype expression in
the separate cholinergic and monoaminergic pathways suggests
that they have different physiological roles in the sleep/wake
regulation (Figure 7). As mentioned above, the administration
of orexin-A to wild-type mice increases wakefulness and reduces
both REM and NREM sleep.121 In the OX1 and OX2 knockout
mice, the effects of orexin-A on wakefulness and NREM sleep
are significantly attenuated compared to the wild-type mice,
OX2 knockouts showing this more prominently. The effect of
orexin-A on REM sleep, instead, is slightly reduced in both of
these orexin receptor knockout mice models. In addition, the
orexin null mice show greater sleep stage transitions than the
OX2 knockouts.130 Altogether, this highlights the importance of
both orexin receptor subtypes for the maintenance of
wakefulness and sleep, but with a dominant role of OX2. These
findings are supported by data from narcoleptic dogs131,139 and
human clinical data of orexin receptor antagonists as insomnia
treatment (see 2.5.1.2 and 2.5.1.3). Additionally, it is suggested
that OX2-selective blockade (by OX2-selective antagonists, 2-
SORAs) would produce more physiologically balanced
NREM/REM profile than blockade by dual antagonists
(DORAs; reviewed in 138). However, the role of OX1 in the
maintenance of wakefulness and sleep is not fully clear, and
thus DORA/2-SORA efficacy differentiation (i.e. whether
DORAs or 2-SORAs are better sleep aids) remains partially
unsolved.
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2.4.3 ADDICTION AND REWARD SEEKING BEHAVIOUR
The first indication of the connection between the orexin system
and addiction came from the clinical data of type I narcolepsy
patients, who rarely develop stimulant abuse, even though
narcolepsy is commonly treated with long-term use of
amphetamines (140, reviewed in 141). In 2005, two research
groups showed that activation of orexin neurons is correlated
with morphine and cocaine seeking, and the seeking behaviour
could be subsequently blocked by a selective OX1
antagonist.142,143 Currently, orexin neurons are suggested to be
critical in high-effort drug seeking behaviour, that is, drug
seeking in situations of high motivational relevance, such as
during physiological need, exposure to threats (i.e. stress), or
reward opportunities.144
Thus, the orexin system would not play a role in the primary
reinforcing effects of drugs of abuse, but rather in the
motivation for seeking them. The motivation for drug reward
can be enhanced by various external stimuli, and it occurs in an
orexin-dependent manner (145, reviewed in 141). Even though
most of the reward/addiction studies utilize OX1 antagonists,
OX2 also has a role in reward seeking; for example alcohol or
nicotine seeking involves OX2 receptors.146–148
2.4.4 STRESS AND STRESS-BASED CONDITIONS
In chronic stress, the hypothalamic–pituitary–adrenal (HPA)
axis has a major role (reviewed in 149). Orexins activate the HPA
axis leading to a release of corticotrophin-releasing hormone,
adrenocorticotropic hormone, and corticosterone, and sends
projections to the brain regions directly responsible for the
production of the corticotrophin releasing hormone. All of these
factors stimulate stress behaviour and suggest a possible
connection between the orexin system and chronic stress.
Dysfunctions in orexin signalling have been reported in
stress-related neuropsychiatric disease states, such as anxiety
(reviewed in 149,150). Orexin neurons are needed for the
development of the panic-prone state in a panic-disorder rodent
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model, which can then be suppressed by silencing the prepro-
orexin gene, or by a high systemic dose of OX1 antagonist.151–153
Furthermore, the OX1-selective antagonist (1-SORA) ACT-
335827 and dual orexin receptor antagonist almorexant have
been studied in anxiety rodent model, in which they both
showed similar anxiolytic-like effects, but almorexant also
decreased wakefulness.154 Thus it seems that of orexin
receptors, OX1 is the main player in anxiety. Apart from anxiety,
symptoms of depression have also been reported to negatively
correlate with orexin levels  (e.g. 151,155–157, reviewed in 149,150).
2.4.5 OTHER THERAPEUTIC OPPORTUNITIES
The initial findings of the physiological relevance of the orexin
system were related to feeding, as the administration of orexin
peptides acutely increased food consumption in rats and mice.45
Even though the orexin-mediated effects on feeding were then
later concluded to be a sum of several functions (such as those
related to sleep/wake regulation, reward seeking, and mood),
the orexin system also has a direct role in energy expenditure
and glucose homeostasis (reviewed in 158). Orexin neurons
control multiple aspects of glucose homeostasis, such as the
sympathetic nervous system output in respond to
hypoglycaemia. Furthermore, orexin tone seems to promote
glucose uptake and control the secretion of pancreatic islet
hormones, contributing to physiologic glucose homeostasis over
the longer-term. The short-term effects of orexins are possibly
mostly OX1-dependent, while the long-term control of energy
expenditure acts via OX2 signalling. However, it should be noted
that most of the studies are conducted with 1-SORA SB-334867,
as OX2-selective variants have not been available until recently,
and thus the role of OX2 is not as thoroughly studied.
The orexin system has also been reported to play a role in
nociception (reviewed in 159). Orexin-A has been shown to be
analgesic in rodent pain models, and this action could be
blocked by the 1-SORA SB-334867.160 These findings are
supported by more recent evidence of the antinociceptive effects
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of orexins in different types of pains (reviewed in 159). Even
though the pain-modulation pathways of orexins are not fully
understood, the antinociceptive effects of orexin-A have been
shown to be more potent than those of orexin-B, and mainly
OX1-mediated.
Prolonged orexin receptor stimulation induces programmed
cell death in colon carcinoma, neuroblastoma, and pancreatic
acinar tumour cell lines (chapter 2.3.3).114–116 Furthermore,
colon carcinoma cells, unlike normal colon epithelium, express
OX1 receptors. Thus, orexin receptor activation has been
suggested to be useful in the treatment of colon cancer, for
example.
2.5 DISCOVERY OF SMALL MOLECULE OREXIN
RECEPTOR MODULATORS
2.5.1 OREXIN RECEPTOR ANTAGONISTS
The search for small molecule orexin receptor ligands started
rapidly after the first indications that the orexin system can be
targeted for sleep-inducing pharmacotherapies. Until 2016,
over 200 patent applications concerning orexin receptor
antagonists had been filed; in 2016 alone, the number of new
patents was still 35 (161, reviewed in 122). Currently, the sleep
disorders are the main indication for DORAs and 2-SORAs,
whereas 1-SORAs are mainly aimed at anxiety and panic
disorders (see chapter 2.4). Additionally, both orexin receptor
subtypes are involved in addiction, which could imply a target
for 1- and 2-SORAs, depending on the drug of abuse.
Until 2016, eight orexin receptor antagonists had reached
human clinical trials, and four DORAs had completed phase II
studies (reviewed in 122). These DORAs are almorexant (Actelion
Pharmaceuticals Ltd.), SB-649868 (GlaxoSmithKline a.k.a
GSK), suvorexant (Merck & Co., Inc), and filorexant (Merck &
Co., Inc), and they will be discussed in detail in chapter 2.5.1.3
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(Figure 10). Of these, suvorexant162 received FDA approval for
the treatment of insomnia in August 2014, becoming the first
orexin receptor antagonist on the market (currently in the
United States and Japan).
All reported orexin receptor ligands (antagonists and
agonists alike) have been initially discovered through high
throughput screening (HTS; see below); whether molecular
modelling has been utilized in the subsequent compound design
is rarely communicated. Nevertheless, several retrospective
docking studies explaining the binding of the discovered
compounds is found from the literature.54–56,163–166 An overview
of binding modes of the co-crystallized antagonists and
computational studies are provided in chapter 2.5.1.4.
2.5.1.1 OX1-selective antagonists
The discovery of the very first orexin receptor antagonists was
reported in 2001.167,168 These compounds were 1,3-biaryl urea-
based 1-SORAs, and they were identified by functional HTS on
CHO cells expressing human OX1 receptors. The structure-
activity relationship (SAR) studies conducted around an initial
HTS hit led to the discovery of SB-334867, a relatively potent
and selective, and brain penetrant OX1 ligand (Figure 8).168
Even though SB-334867 lacked oral bioavailability and had
rather wide off-target activity, it demonstrated in vivo efficacy
in preclinical rodent models, and has remained as a commonly
used research tool; SB-334867 is used in almost 500
publications concerning orexin pharmacology (see e.g. 169,170;
reviewed in 171). Shortly after SB-334867, a discovery of SB-
674042 (Figure 8) and its tritiated analogue [3H]-SB-674042,
the first OX1-receptor selective radioligand, was announced.172
Interestingly, SB-674042 is the 1-SORA utilized for
determination of the OX1 crystal structure (see chapter
2.5.1.4).54
Apart from 1,3-biaryl ureas, two series of
tetrahydroisoquinolines, close structural analogues of the dual
orexin receptor antagonist almorexant (Figure 10), and a set of
Review of the literature
52
morphinan compounds have been reported as potent 1-
SORAs.154,164,173 These compounds show over 70-fold selectivity
towards OX1, and they reduce anxiety, cocaine-seeking, and
physical dependence to morphine in rats.
Figure 8. Examples of 1-SORAs. Affinities are as reported in 154,164,167,172,173.
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2.5.1.2 OX2-selective antagonists
Shortly after the first 1-SORAs, the first series of 2-SORAs were
introduced by Hirose et al.167,174 They reported a
tetrahydroisoquinoline-structured HTS hit and a SAR
optimization campaign leading to a 2-SORA with over 250-fold
selectivity over OX1 (Figure 9). About a year later, 4-phenyl-
[1,3]dioxane urea compounds were identified as 2-SORAs by a
similar kind of approach; the most promising compound of this
series, JNJ-1037049 (Figure 9), had somewhat better binding
affinities compared to the previously reported
tetrahydroisoquinoline and also improved selectivity over
OX1.175 Further experiments with JNJ-1037049 showed that
this compound decreased the latency to persistent sleep and
increased REM and NREM sleep, offering the first proof of
concept of preclinical efficacy of OX2-selective ligand in a rodent
sleep model.176
In 2009, Malherbe et al. reported 2-SORA EMPA (Figure 9),
and subsequently, a tritiated [3H]-EMPA, the first OX2 selective
radioligand.177 Quite recently, the three-dimensional structure
of OX2 in complex with EMPA was reported (see chapter
2.5.1.4).56 In addition to these, benzoxazepine-scaffolded
compounds have also been reported as 2-SORAs (Figure 9).178
In 2016, 2-SORAs were a leading trend in the patent
literature of the field of orexin receptor antagonists.161 This,
however, is not too unexpected, as several 2-SORAs have
provided promising preclinical data in the sleep models (e.g.
references 179–181, reviewed in 122). Until 2016, two 2-SORAs had
entered clinical trials, MK-1064 by Merck and JNJ-42847922
by Janssen Pharmaceuticals (Figure 9), and until 2017 the
number has doubled (179,182, reviewed in 138) Of these, MK-1064
has been reported to have similar effects on the sleep of healthy
subjects as DORAs.179
Review of the literature
54
Figure 9. Examples of 2-SORAs as presented in 174,175,177,179,182,183.
2.5.1.3 Dual orexin receptor antagonists
In 2003, Koberstain et al. published the first series of
compounds acting as DORAs.184 In this study, they describe a
structural optimization of the tetrahydroisoquinoline
compound identified by HTS, utilizing solution-phase
chemistry combined with automated purification. The versatile
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structural optimization led to the discovery of ACT-078573,
currently known as almorexant (Figure 10).127,184 Almorexant
has a high affinity on both orexin receptor subtypes (13 nM on
OX1 and 8 nM on OX2), efficient brain penetration, over 650-
fold selectivity towards a large panel of targets, and decent
bioavailability in rats and dogs. Furthermore, almorexant
showed significant reductions in active wake and concomitant
increases in REM and NREM sleep in these animal models and
no signs of promotion of cataplexy. Thus, almorexant, as the
first orexin receptor antagonist, entered clinical trials, where it
was generally well tolerated and significantly improved sleep
efficiency and maintenance (reviewed in 171). Even though the
development of almorexant was discontinued in 2011, due to
‘infrequent transient increases in liver enzymes’185, it offered a
solid proof of concept of deploying DORAs in the treatment of
insomnia.
Other DORAs have also entered clinical trials, and of these
SB-649868186, suvorexant (MK-4305),162,187,188 and filorexant
(MK-6096)189 have been reported to have completed phase II
(Figure 10; reviewed in 122). SB-649868, reported in 2009 as a
result of SAR analysis of piperidine bis-amides, is a DORA with
a sub-nanomolar affinities and promising in vivo activity and
pharmacokinetic profile in rats.186,190 As almorexant, SB-
649868 has also been reported to have a remarkably good sleep
efficacy, but metabolic studies have demonstrated a risk of
biologically relevant nucleophiles among its metabolic
intermediates, indicating  possible idiosyncratic toxicity
(reviewed in 122). After these reports, the development of SB-
649868 was discontinued due to unspecified reasons (reviewed
in 138).
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Figure 10. Examples of DORAs. Binding affinities as reported in
127,162,186,189,191.
In 2009, Whitman and co-workers reported a series of N,N-
disubstituted-1,4-diazepanes, identified as orexin receptor
ligands by HTS.192 After a thorough structural optimization of
the ‘eastern’ and ‘western’ part of the molecule, they disclosed
‘compound 5’ (Figure 11) with low nanomolar binding affinities
towards OX1 and OX2. To guide further compound
development, compound 5 underwent conformational analysis
by NMR spectroscopy, X-ray crystallization and molecular
modelling.192 Together these studies indicated, that compound
5 adapts a U-shaped conformation due to energetically
favourable intramolecular -stacking interactions and the
twist-boat conformation of the diazepane ring. Subsequently,
the U-shape was tested by a macrocyclic compound locked into
such a conformation; the higher binding affinity of the
macrocycle, compared to that of the open precursor, was the
first indication of orexin receptor antagonists adopting U-
shaped bioactive conformation. Later, the U-shape was
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established by co-crystallization of suvorexant with OX1 and
OX2 receptors.54,55
The conformational studies led to the development of a
series of compounds bearing modification in their central
diazepane ring; the aim of these was to lock the compounds to
the preferred U-shaped conformation (e.g. ‘Compound 8a’ in
Figure 11).193 Simultaneously, the original lead compound 5 was
modified further, and after several rounds of modifications the
structure of MK-4305, currently known as suvorexant, was
disclosed (Figure 10; Figure 11).162,188
Figure 11. The discovery of suvorexant. The presented structures and
affinities are disclosed in 162,187,192,193.
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Interestingly, suvorexant and EMPA have similar binding
affinities for OX2 (Ki’s approximately 1.3 nM in 194), but the
dissociation rate of suvorexant is more than ten-fold lower than
that of EMPA.194 Furthermore, the dissociation kinetics of
almorexant is even slower than that of suvorexant.177,194 This
means that the two orexin receptor antagonists that are effective
in clinical trials display notably slow dissociation kinetics, which
could contribute to their mechanism of action. In general, slow
dissociation kinetics of antagonists of peptide receptors seems
to be important for their in vivo efficacy (e.g. in case of
neurokinin 1 receptor195).
At about the same time as N,N-disubstituted-1,4-diazepanes,
piperidine ethers were reported as potent DORAs.189,196 Guided
by a thorough conformational analysis, modifications to these
lead to the disclosure of the structure of MK-6096, a.k.a.
filorexant (Figure 10). Filorexant bears a 2,5-trans-diaxial
substitution in its piperidine ring allowing intramolecular -
stacking and U-shape formation, which is hypothesised to be
crucial also for its bioactivity.196 In addition to a favourable
ADME/T profile, filorexant has shown improved efficacy in
preclinical studies compared to suvorexant, likely due to its
higher unbound plasma concentration in vivo (189, reviewed in
122), making it a promising clinical candidate.
Apart from tetrahydroisoquinolines, diazepanes, and
piperidines, a recent study of Yoshida et al. reports the
development of a series of cyclopropane-cored DORAs.191 A
detailed SAR optimization led to selection of E2006 aka
lemborexant (Figure 10) for further clinical evaluation. In 2017,
lemborexant was reported to have successfully entered phase II
clinical trials (reviewed in 138).
2.5.1.4 Binding modes and molecular modelling of orexin
receptor antagonists
Both orexin receptor subtypes have been crystallized in complex
with the DORA suvorexant (PDB IDs: 4ZJ8 and 4S0V, on OX1
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and OX2, respectively).54,55 Additionally, OX1 has been
crystallized with the 1-SORA SB-674042 (4ZJC)54, whereas the
structure of OX2 is solved in complex with the 2-SORA EMPA
(5WQC and 5WS3).56 The structures of OX1 and OX2 in complex
with suvorexant are highly similar;54,55,197 the C  root mean
square deviation (rmsd) over 282 C  atoms of the superimposed
structures is only 0.4 Å. There is a two-amino-acid difference at
the antagonist binding sites of orexin receptors—S2.61T and
A3.33T in OX1 and OX2, respectively—making the OX1 binding
site slightly larger. Additionally, the crystal structures of OX2
have water molecules in the binding site, but these are not
detected in OX1 structures. However, that is almost certainly
due to the lower resolutions of the OX1 structures; OX1
structures are solved at 2.75 Å and 2.83 Å resolutions
(suvorexant and SB-674042, respectively), whereas for OX2
structures the resolutions are 2.5 Å (suvorexant), 1.96 Å and 2.3
Å (EMPA).
Suvorexant adopts almost identical U-shaped binding
conformation in both orexin receptor subtypes (Figure 12A–B),
and the binding conformation of SB-674042 in OX1 is highly
similar (Figure 12C). The carbonyl oxygen of all these ligands
form a hydrogen bond with Asn6.55. In OX2, the hydrogen bond
network continues from the carbonyl oxygen of suvorexant to a
crystallographic water molecule, His7.39 and Asp2.65 (Figure
12B). It is worth noting that the His7.39–Asp2.65 salt bridge is
present in all antagonist-bound orexin receptor crystal
structures (Figure 12).
Review of the literature
60
Figure 12. A. The binding pose of suvorexant in OX1 (pdb ID: 4ZJ8). B. The
binding pose of SB-674042 in OX1 (pdb ID: 4ZJC). C. The binding pose of
suvorexant in OX2 (pdb ID: 4S0V). D. The binding pose of EMPA in OX2 (pdb
ID: 5WQC). In OX1 structures (A and B) ligands and amino acid residues
within 3.5 Å these ligands are shown as wheat sticks. In OX2 structures (C
and D) the ligands and amino acid residues within 3.5 Å of these ligands and
co-crystallized water molecules are shown as cobalt blue sticks. Colour code
is as follows: wheat / cobalt blue / white, carbon; red, oxygen; blue, nitrogen;
yellow, sulphur; green, chlorine; light blue, fluorine. Green dashes represent
possible hydrogen bonds, red spheres the crystallographic water molecules
and the grey surfaces the space each ligand occupies in the binding pocket.
The subset of binding site amino acid residues shown are selected based on
the published point mutation data. View is from the extracellular side of the
receptor, from the direction of TM7.
The 2-SORA EMPA is the only co-crystallized orexin
receptor ligand reported thus far that does not adopt a U-shape
and lacks direct interaction with Asn6.55 (Figure 12D). The
sulphonamide group of EMPA can instead form a hydrogen
bond with Gln4.60, and interact via crystallographic water
molecules with Gln3.32 and His7.39.
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Prior to the orexin receptor crystal structures, a couple of
molecular modelling studies involving orexin receptors were
published.57,60 The study of Malherbe et al.57 focused on the
retrospective analysis the results of the orexin receptor mutants
utilizing homology models and molecular docking. The study of
Heifetz et al.60 had similar aims to those of Malherbe and co-
workers’, but with additional molecular dynamics (MD)
simulation data. Of these, the binding site amino acid residues
highlighted by the computational studies are mainly verified by
the crystal structures, even though the reported binding poses
are not equivalent to the co-crystallized ones.
The release of the orexin receptor crystal structures led to a
‘second generation’ of computational studies explaining the
ligand binding of orexin receptors. Several reports have been
published explaining the binging interactions of a wide variety
of orexin receptor ligands,55,163,164  orexin receptor activation
(see 2.5.2.2 below),165,166,198 and subtype selectivity.54,56 As an
example, Heifetz et al. further explored the amino acid residues
contributing to the binding of suvorexant to OX2 utilizing the
molecular orbital method.163 This study identified residues
Pro3.29, Gln3.32, Gln4.60, Gluxl2.52, Phe5.42, Ile6.51, Asn6.55, His7.39,
and Tyr7.43 to contribute to the binding; of these Gln3.32, Phe5.42,
Ile6.51, His7.39, and Tyr7.43 are in accordance with the mutation
studies of OX2 with almorexant and EMPA.57 Interestingly, their
results highlighted the importance of Gluxl2.52, located within
the -hairpin structure (see chapter 2.2.3), for the binding of
suvorexant. Even though there is no suitable hydrogen bond
donor in the structure of suvorexant, Heifetz et al. suggested
that its 1,4-diazepane ring has a positive electrostatic field,
which could interact with the negative field of the side chain of
Gluxl2.52.
It is suggested that SB-674042 has improved shape-
complementary with the binding site of OX1 compared to that of
OX2 in addition to the required interactions leading to OX1-
selectivity.54 The reported molecular docking, MD simulations,
and site-directed mutagenesis studies with EMPA, instead, have
suggested specifically the importance of the residues Thr2.61 and
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Thr3.33 for their OX2-selectivity.54,56,57 Interestingly, the methyl
groups of these residues are within 4 Å from EMPA (of its
methoxy and sulphonamide groups, respectively), but the
hydroxyl groups of these side chains are too far for hydrogen
bonding (Figure 12D). This suggests that also in the case of
EMPA, subtype selectivity may originate from the suitable
binding site complementarity.
2.5.2 ACTIVATING THE OREXIN SYSTEM
Unlike the successful development of numerous orexin receptor
antagonists, activation of the orexin system has relied mainly on
the native orexin peptides (reviewed e.g. in 171). However, small
molecule-sized orexin receptor activators would be of interest
especially in targeting narcolepsy (see chapter 2.4.2); the drugs
currently used for type I narcolepsy do not target the causative
deficits in orexin levels but rather act as CNS stimulants
(reviewed in 138). There are two possible ways to enhance the
activity of the orexin system: orexin receptor potentiators,
which enhance the actions of the endogenous orexin peptides,
or direct orexin receptor agonists.
2.5.2.1 Orexin receptor potentiators
One series of orexin receptor potentiators is found in the
literature.199 In that study, Lee et al. reported peptoids
discovered by a microarray-based, two-color, cell-binding
screen, and structural optimization, which led to DORAs with
low micromolar affinity. Interestingly, three compounds
increased the potency of orexin-A in their assay set-up, and
when studied further, the best of them, OBPt-9 (Figure 13),
showed a 2.5-fold maximum potentiation of a response to a
small concentration of orexin-A (corresponding to its EC20 in
adenylyl cyclase assay). Although OBPt-9 was reported to have
entered in vivo testing, no such a report is available to date.
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Additionally, in their report, Lee et al. provide no data regarding
orexin receptor mediation of the observed potentiation.
2.5.2.2 Orexin receptor agonists
Only one series of orexin receptor agonists with significant
efficacy has been reported.165 The lead compound of this study,
Nag26 (Figure 13), has an EC50 of 1.62 and 0.023 μM, and an
Emax of 100% and 98% on OX1 and OX2, respectively (in Ca2+
elevation assay in recombinant CHO cells). Nag26 was
discovered by a thorough structural optimization of hits of a
HTS campaign, and it bears a secondary sulphonamide, which
is reported to be crucial for its activity. As the water solubility of
Nag26 was not considered high enough for in vivo testing, it was
modified further by introducing the 2-dimethylamino group on
the B-ring instead of the 3-methyl of Nag26 (Figure 13). The
resulting YNT-185 (Figure 13) was characterized in vivo,
wherein it suppressed cataplexy-like episodes in orexin
knockout and orexin neuron-ablated mice, and promoted
wakefulness in wild-type mice upon i.c.v. administration.134
Altogether, these results provide a proof-of-concept for treating
narcolepsy–cataplexy with OX2 agonists.
The binding interactions of Nag26 and OX2, and possible
attributes of receptor activation, have been studied by molecular
docking.165,166 Together with the disclosure of Nag26, Nagahara
et al. published a docking study where they suggested Nag26 to
occupy the same binding pocket as suvorexant, but adopt an
extended conformation reaching its aromatic A-ring substituent
towards TM5 and TM6. Thus, they hypothesized that binding of
Nag26 would allow interactions leading to the inward
movement of TM5 and TM6 and therewith receptor activation.
Another report of molecular docking of Nag26 was published by
Heifetz et al; they present two docking poses of Nag26, one
similar to that of Nagahara et al. and another resembling the U-
shape of suvorexant.166 In this study, the binding interactions of
Nag26 are discussed in the context of the previously published,
site-directed mutagenesis data (see chapter 2.2.3). Amino acid
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residues Thr2.61, Gln3.32, Phe5.42, Tyr5.47, and Tyr6.48 have been
shown to affect the potency or efficacy or both of orexin-A
(investigated by alanine mutations), and these residues also
interact with the Nag26 in the reported docking poses. Thus, the
authors discuss the involvement of the TM3 6 interface, a
common interaction partner with an agonist in the structures of
Rhodopsin family GPCRs (see also 2.1.3), in Nag26-mediated
orexin receptor activation.
Figure 13. Orexin receptor activators—full agonists Nag26 and YNT-185, the
putative potentiator OBPt-9, and the agonist hit compounds Yan7874 and
Cano 28 reported in patent literature.
In addition to Nag26 and YNT-185, reports of compounds
with weak orexin receptor agonism activity have been
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published.200,201 These compounds by Yanagisawa and Cano et
al. are found in the patent literature, and include hardly any
pharmacological data. The lead compound of Yanagisawa,
Yan7874 (Figure 13), is said to produce a six-fold elevation of
Ca2+ concentration at 10 μM compound concentration in OX2-
expressing CHO cells, and a much weaker response in OX1-
expressing cells. The patent also describes SARs for a small
series of compounds showing the importance of the chiral
alcohol and imine functionalities, but without disclosing any
stereochemistry.
The patent of Cano et al. presents a series of 2-(2-
aminophenoxy)-3-chloronaphthalene-1,4-dione compounds,
whose agonist activity towards OX2 is assessed at 50 μM
concentration. The patent claims the lead compound (Figure 13)
to produce 93% activation of OX2 receptors, however, the used
method is not fully described, and thus comparing the results
with the other studies is not straightforward.
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3 AIMS OF THE STUDY
At the commencement of this thesis work, neither small
molecular orexin receptor agonists nor structural data of orexin
receptors were reported in the scientific literature (Figure 1).
Thus, relying on the available data, this study sought to
understand binding and activation attributes of the orexin
receptor ligands (by computational methods) and then
subsequently apply the gained knowledge in finding novel
orexin receptor ligands (preferably activators).
The specific aims were:
1. To understand the chemical features that make
small molecules and peptides bind to, and activate,
orexin receptors.
2. To develop pharmacophoric representations of the
features that are important for orexin receptor
binding or activation or both.
3. To find new small molecular ligands that bind to
and activate orexin receptors.
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4 MATERIALS AND METHODS
The methods used in the publications I–IV are summarized in
Table 2.
Table 2. Summary of the used methods.
Computational method Publication
Pharmacophore modelling I, IV
Molecular docking I, III
Virtual screening I, III
R-group analysis III
In vitro method
Ca2+ elevation assay I–IV
Competition binding assay I, III
Phospholipase C assay II
Adenylyl cyclase assay II
Cell viability measurements II
4.1 COMPUTATIONAL METHODS
4.1.1 PHARMACOPHORE MODELLING AND VIRTUAL
SCREENING
A pharmacophore model is a combination of chemical features
in three dimensional space, which are required for triggering a
biological response (such as binding to a receptor; reviewed e.g.
in 202). These chemical features include hydrogen bond donors
and acceptors, aromatic rings, and positive, negative, or
hydrophobic point features. Pharmacophore models can be
constructed either by a superimposition of known bioactive
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compounds of interest (a training set) and selecting the similar
chemical features for the pharmacophore, or the features can be
selected based on receptor-ligand interactions (so-called
shared-feature and structure-based pharmacophores,
respectively). The classification performance of the
pharmacophore is commonly tested with a set of compounds
including both active ligands and structurally related inactive
compounds (a test set); each compound in the test set is overlaid
with the pharmacophore model and classified either as an active
(match) or inactive (non-match) based on the overlay or RMSD
of the pharmacophoric features, depending on the used
algorithm.
In publication I, we constructed both shared-feature and
structure-based pharmacophores with Discovery Studio 3.5
software203. For structure-based pharmacophores, docking
complexes of orexin receptor ligands and NTS1-based OX1
homology model198 were used for guiding the feature selection.
Docking was conducted by the Induced fit protocol of
Schrödinger Glide software (2013v2).204 A test set of 162 DORAs
and 1-SORAs collected from the literature were used, in addition
to 41 known decoys published together with the active ligands.
Smaller subsets of these active compounds were used as a
training set for common-feature pharmacophores.
The classification performance of the models was defined by
calculating the sensitivity (Eq 1) and the specificity (Eq 2) of
retrieving the test set compounds. Receiver operator curves
(ROC) were generated, and the area under the curve (AUC)
calculated by Schrödinger Maestro 2013v2 software204.
= + ( . 1)
= + ( . 2)
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In equations 1 and 2, TP refers to true positives (the number
of active compounds that are correctly classified), and FN to
false negatives (the number of active compounds that are
incorrectly classified). TN means true negatives (the number
inactive compounds that are correctly classified), and FP false
positives (the number of inactive compounds that are
incorrectly classified).
In publication IV, Discovery studio 4.5 software205 and
common-feature pharmacophores were employed to explain
the SARs of the azulene hit compounds. The active compounds
were superimposed and pharmacophore models constructed
guided by the superimposition. The classification power (active
compounds of publications III and IV from the inactive ones)
was defined by monitoring the sensitivity and specificity (Eq1
and Eq2).
Pharmacophore models are commonly utilized as virtual
screening filters to select the most promising compounds
among the compound libraries for biological testing (reviewed
in 202). In publication I, the pharmacophore model with the best
sensitivity and specificity factors was utilized for a virtual screen
of the compound library of the Finnish Drug Discovery and
Chemical Biology consortium (http://ddcb.fi/en/; v2011, about
137 000 compounds). The screening was conducted with default
parameters using Discovery Studio 3.5.203 The retrieved hit list
of 800 compounds was post-processed with molecular weight
(>400 g/mol passing) and reactivity filters (REOS), as well as
visual examination. Additionally, the absence of possible PAINS
containing structures was checked by FAF-Drugs2.206 The final
hit list consisted of 395 compounds.
4.1.2 MOLECULAR DOCKING AND DOCKING-BASED
VIRTUAL SCREENING
Molecular docking aims to predict the binding mode of a ligand
to a protein binding site, and it is nowadays an essential
structure-based drug discovery strategy (reviewed e.g. in 207). As
a calculation, docking relies on scoring functions, both during
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the exploration of the binding conformation space of a ligand
and evaluation of the final binding poses. Currently applied
scoring functions can be roughly divided into three classes:
force-field based; empirical; and knowledge-based scoring
functions. The force field-based scoring functions use classic
force fields to compute the noncovalent protein–ligand
interactions (e.g. van der Waals and electrostatic energies). The
empirical scoring functions calculate the overall binding free
energies of the protein–ligand complexes from several energetic
terms, including hydrogen bond and hydrophobic interactions.
Finally, the knowledge-based scoring functions consider the
protein–ligand interactions as a sum of distance-dependent
statistical potentials, deducted from the structural information
of the solved protein–ligand complexes, between the ligand and
the target.
In publications I and III, we utilized docking software Glide
of the molecular modelling package Schrödinger Maestro,
which applies empirical scoring function GlideScore.204,208–210
In publication I, a homology model of OX1 and crystal structures
of OX1 and OX2 were utilized, and Induced Fit docking protocol
used with default parameters. At an early stage, a set of
reference ligands were docked to the NTS1-based homology
model of OX1198 to guide the pharmacophore modelling
(described in 4.1.1). The binding site was defined by the centroid
of the coordinates of the amino acid residues that were reported
important for orexin receptor activation (see 2.2.3). The
retrospective docking was conducted to the crystal structures of
OX1 and OX2, which were published while our study was
ongoing, and the binding site was defined by the location of the
co-crystallized suvorexant.54,55 Docking to the OX2 crystal
structures was conducted both in presence and absence of the
binding site water molecules (waters 4021 and 4025).
Docking is also commonly utilized in virtual screening
(reviewed in 207). In the docking-based virtual screening, the
compounds of a compound library are individually docked to a
target binding site and ranked based on their ‘fit’. The top-
ranking compounds are assumed to bind better to the target,
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and thus are worth undergoing biological testing. However, the
docking protocols, and especially scoring, are limited by
mathematical approximations, and thus monitoring the quality
of the screening (e.g. enriching the library with active reference
ligands and monitoring their scoring) and the post-processing
of the hit lists (e.g. by additional scoring and/or filtering
methods and visual examination) is utmost important.
In publication III, we conducted a docking-based virtual
screen on an in-house combinatory virtual library of 70038
azulene-based compounds to OX2, which was the only orexin
receptor crystal structure available at the time.55 The screening
compounds were aimed to be synthetically accessible,211,212 and
the lipophilic azulene ring was envisaged to mimic the
amphipatic -helical C-terminus of orexin-A.46,198 The database
was built with a combinatory database building tool of
Schrödinger Maestro software.213
For screening, Glide was used with SP parameters, and the
binding site was defined by the location of co-crystallized
suvorexant. To monitor the performance of the docking, the
virtual library was seeded with 117 DORAs or 2-SORAs. The
docking protocol retrieved 25% of the active compounds in the
top 10% of the database, leading to the AUC of 0.75.
Furthermore, suvorexant was docked among the active
compounds, and the docked conformation compared to that
present in the OX2 crystal structure. Docked suvorexant scored
in the top 1.6% of the library and its conformation was highly
similar to the binding conformation in the crystal structure
(pairwise heavy atom RMSD 0.54).
4.1.3 R-GROUP AND SAR ANALYSES
Structure-activity relationship (SAR) analysis relies on the
assumption that the activity of the compound is a function of its
structure.214 Thus, analysing the structures of active and
inactive compounds provides insights into their activity and
rationalizes the structural optimization of the compounds. In
publication III, this idea was utilized in post-processing of the
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virtual screening hit list—it was hypothesised that the more
often certain R-groups occur among the top-scoring poses, the
more important this R-group would be for the activity of the
compounds. Thus, we analysed the 5% top-scoring poses (i.e.
7200 poses) using the R-group analysis tool of Schrödinger
Canvas.208 The understanding gained regarding the most
favourable R-groups supported the visual examination of the
200 top-scoring docking poses, and the final selection of the
compounds to be synthesized.
4.2 IN VITRO METHODS
4.2.1 CELL CULTURE AND MEDIA
CHO-K1 cells expressing human OX1 and OX2 receptors (CHO-
hOX1 and CHO-hOX2, respectively72,215) as well as ctrl CHO-K1
cells not expressing orexin receptors (ctrl CHO cells) were
cultured in Ham’s F12 medium (Gibco/Life Technologies,
Paisley, UK) + supplements, and neuro-2a cells in Dulbecco’s
modified Eagle’s medium (Gibco/Life Technologies) +
supplements on plastic cell culture dishes (56 cm2 bottom area;
Greiner Bio-One GmbH, Frickenhausen, Germany) as described
in 73,77.
Experiments were run in hepes-buffered medium (HBM;
137 mM NaCl, 5 mM KCl, 1.2 mM MgCl2, 0.44 mM KH2PO4, 4.2
mM NaHCO3, 20 mM Hepes, 10 mM glucose, and 1 mM CaCl2,
pH adjusted to 7.4 with NaOH). For Ca2+ measurements, HBM
was supplemented with 1 mM probenecid, to inhibit probe
extrusion from the cytosol, and the ligands were diluted in this
same buffer containing additionally 0.05% w/v stripped bovine
serum albumin (to aid in keeping the lipophilic compounds in
solution). For binding, HBM with 0.1% w/v stripped bovine
serum albumin (to reduce also nonspecific binding of [125I]-
orexin-A) and 30 M dyngo 4a (to block receptor
internalization) was used. Furthermore, for PLC assay, HBM
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supplemented with 10 mM LiCl was used, and for AC assay
HBM was supplemented with 500 M cyclic nucleotide PDE
inhibitor and 3 M PKC inhibitor.
4.2.2 CA2+ ELEVATION ASSAY
Intracellular Ca2+ elevation is a prominent response to orexin
receptor activation, as reviewed in chapter 2.3.1. Thus, a
fluorescence-based Ca2+ elevation assay was used to screen the
agonist and antagonist activities of the compounds towards
orexin receptors. Additionally, Ki values were determined for
the most promising binding assay hits (see below) orthogonally
utilizing Ca2+ elevation assay, as well as studying the orexin-
receptor-mediation of the observed agonist activities, and the
potentiation effect the hit compounds had on the Ca2+ responses
to orexin-A.
The cells, 1.5×104 per well, were plated on black, clear
bottom half-area 96-well plates. Twenty-four hours later, cell
culture medium was removed, and the cells were treated with
loading solution composed of FLIPR Calcium 4 Assay Kit
(Molecular Devices, Sunnyvale, CA) dissolved in and diluted
with HBM, for 60 min at 37 °C. Then, the plate was placed in a
FlexStation 3 fluorescence plate reader (Molecular Devices) and
intracellular Ca2+ levels were measured as fluorescence changes
(excitation at 485 nm, emission at 525 nm) at 37 °C for 150 s.
The screening assay was designed to detect both agonist and
antagonist properties of the test compounds (Figure 14). The
agonist responses were detected within the first round of
measurements; in the first round, the baseline was collected for
30 s of each well, after which the test compounds (in the
corresponding HBM) were added and the response collected for
another 120 s. To widen the detection window, the delayed
agonist response was assessed for 30 s, 30 min after agonist
addition. In the second round, 0.3 nM orexin-A was added to
each well, revealing compounds inhibiting orexin-A response.
For both tests, vehicle was included in each column of wells to
serve as both negative (1st round) and positive (2nd round)
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control. The responses to each compound were reported as a
percentage of Emax of orexin-A.
Figure 14. The design of the Ca2+ elevation-based screening assay. First the
baseline is collected for 30 s, after which the test compounds are added, and
agonists detected as a direct Ca2+ response (measured for 120 s; green line).
Then, 30 min later, the measurement is repeated; the baseline of this round
reveals possible compounds with e.g. slow association kinetics. After 30 s,
0.3 nM orexin-A is added; possible antagonists are detected by the blockade
of the response to orexin-A (measured again for 120 s, orange line).
For Ki measurements, the test compounds were added in the
wells according to the procedure for the first round as described
above, and the plate was measured once. Then, 30 min later, 0.3
nM orexin-A was added as a stimulant (2nd addition) and the
measurement was repeated.
For validation of the agonist activities, control antagonists
SB-334867 and TCS-1102 were added to wells manually, when
applicable, and incubated for 10–30 min before the
measurement, after which the test compounds were added, and
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the plate measured according to the first round procedure. SB-
334867 and TCS-1102 have low nanomolar binding
affinities,168,216 and they are thus expected to block the orexin
receptor-mediated fraction of the responses to the test
compounds.
For potentiation studies, the orexin-A/compound and
ATP/compound mixtures were added to the cells and measured
as for the agonist validation. Prior to the analysis of the
potentiation effect of the compounds triggering Ca2+ elevation
on their own, the compound-mediated Ca2+ responses were
subtracted from the responses to orexin-A/compound and
ATP/compound mixtures. To rule out the effect of intracellular
Ca2+ on the observed potentiation, two sets of controls were
utilized: 10 nM ATP (no measurable Ca2+ elevation of its own)
and 30 nM ATP (Ca2+ elevation of a similar magnitude than our
agonistic hits at 10 μM concentration). The potentiation effects
of the compounds causing no Ca2+ elevation were compared to
the 10 nM ATP control, whereas the potentiation effects of the
compounds with Ca2+ response were compared to 30 nM ATP
control.
4.2.3 [125I]-OREXIN-A COMPETITION BINDING ASSAY
Binding of the test compounds was assessed in intact cells, as on
CHO cells [125I]-orexin-A cannot be used with cell homogenates
or membrane preparations.97 The cells (1.5×104 per well) were
plated on white clear bottom half-area 96-well plates, and 24 h
later the culture medium was exchanged for HBM ± 10 M TCS-
1102 (to determine nonspecific binding), and after a 10 min
incubation 0.05 nM [125I]-orexin-A (publication I) or 1 nM
[125I]-orexin-A/orexin-A mixture (1:20, publication III) mixed
with each test compound was added. Dilution series of orexin-A
and SB-334867 were used as controls. After a 90 min incubation
at room temperature, the medium was removed by water
suction and the wells were allowed to dry at 37 °C. Scintillation
cocktail (Ultima Gold; PerkinElmer) was added, and the plates
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were incubated overnight and counted in a Wallac Microbeta
Trilux microplate liquid scintillation counter (PerkinElmer).
4.2.4 PHOSPHOLIPASE C ASSAY
Phospholipase C assay was employed to investigate the
downstream signalling of Yan7874 (publication II). The cells,
2.6×104 per well, were plated on clear 48-well plates. After 24 h,
they were labelled with 3 Ci/mL [3H]-inositol (for 20 h). The
medium was removed, and the cells were incubated in HBM for
30 min at 37°C. The inhibitors TCS-1102 (orexin receptor
antagonist, to check the orexin-receptor-mediation of the
observed response) or UBO-QIC (Gq inhibitor, to check the Gq-
mediation of the response) were also included in this incubation
when applicable.
The cells were stimulated for 10 or 30 min, then the medium
was rapidly removed, and the reactions stopped by ice-cold
0.4 M perchloric acid and freezing. The samples were thawed
and neutralized (0.36 M KOH + 0.3 M KHCO3), and the
insoluble fragments spun down. Anion-exchange
chromatography was used for isolation of the total inositol
phosphate fraction of the supernatants, and the radioactivity
determined by scintillation counting (HiSafe 3 scintillation
cocktail and Wallac 1415 liquid scintillation counter;
PerkinElmer).
4.2.5 ADENYLYL CYCLASE ASSAY
For AC experiments with Yan7874 (publication II), the cells
were pre-treated either for 20 h with cholera toxin (CTx; 1000
ng/mL; AC inhibition studies) or for 36 h with pertussis toxin
(PTx; 300 ng/mL; AC activation studies). The cells, 2.4–
3.0×104 per well, were plated on 48-well plates. Forty-eight
hours after the plating, the cells were labelled for 2 h with 5
Ci/mL [3H]-adenine. Then, they were washed once with PBS,
and HBM was added. The cells were incubated for 30 min at
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37°C before adding the stimulants. After 10-min stimulation at
37°C, the reactions were terminated with ice-cold perchloric
acid and rapid freezing. After thawing, the insoluble fragments
were spun down, and the [3H]-ATP/ADP and [3H]-cAMP
fractions were isolated by sequential Dowex-alumina
chromatography. Radioactivity was determined from the
fractions with scintillation counting as in the PLC assay.
4.2.6 CELL VIABILITY AND CELL DEATH
To assess the cell viability and death after Yan7874 treatment,
microscopic observations were employed, in addition to
quantitative assessment of the cell numbers, and cell viability
and necrosis by a plate reader. Cells were seeded on black, clear
bottom 96-well plates (0.75–1.5×104 per well, depending on the
experiment time) for the plate reader assay, and treated with
test compounds after 24 h. Bright-field microscopic observation
was carried out once every 24 h up to 72 h (Olympus CKX41
microscope with Canon EOS 600D digital camera). A robust cell
death was seen after 24 h of the treatment.
Phase contrast microscopy assesses only the morphological
features of the cells, and thus  fluorescent microscopy was used
for studying the cell death more thoroughly (Nikon TE2000
with 20×/0.75 air objective and NIS Elements AR software;
Nikon, Tokyo, Japan; and an Andor iXon 885 camera; Andor
Technology Ltd., Belfast, UK). For this, the cells were stained
with Hoechst, PI (propidium iodide) and FDA (fluorescein
diacetate). Hoechst stains all nuclei, but the morphological
markers of the nuclei can be told apart (see chapter 2.3.3). PI
can only permeate damaged plasma membranes and stains thus
the nuclei of necrotic cells. FDA (non-fluorescent) is hydrolysed
in the cytoplasm of viable cells to fluorescent fluorescein, which
stays only in the cells with intact membranes; FDA is a measure
of both cell viability and membrane integrity.
For plate reader measurements, the cells were stained as
above.  After the incubation, the fluorescence was read using
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FlexStation 3 at the wavelengths 352 nm/455 nm (Hoechst),
480 nm/525 nm (FDA), and 538/617 nm (PI).
4.2.7 DATA ANALYSIS
All data are presented as mean ± SEM. Student's non-paired or
paired two-tailed t-test (with Bonferroni correction for multiple
comparisons) was used for statistical comparisons.
Significances are as follows: ns (not significant), P > 0.05; *P <
0.05; **P < 0.01; ***P < 0.001. Microsoft Excel was used for all
data visualizations and analyses including curve fitting. For Ca2+
measurements, Ki values were calculated from the determined
IC50 values using the Cheng Prusoff equation.217 Binding was
analysed by Equation 3 and the Ki values calculated by
Equation 4.
( )= ( )[ ] ( )[ ] + ( ) ( . 3)
( ) = ( )( - ) ( - ) ( . 4)
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5 RESULTS AND DISCUSSION
5.1 PHARMACOPHORE MODELLING
(PUBLICATION I)
Orexin receptor crystal structures were unavailable at the
commencement of this investigation (Figure 1). Thus, we
employed homology modelling and docking of orexin peptides,
orexin receptor antagonists, and patented agonist Yan7874  to
gain insight into molecular features that could contribute to
orexin receptor binding and activation (198 and publication I).
Even though a homology model of OX1198 was used, we intended
to target both orexin receptor subtypes, as their binding sites are
nearly identical (chapter 2.5.1.4). We sought to integrate the
identified features to a pharmacophore model, which would be
able to uncover both novel agonists and antagonists of orexin
receptors. The hypothesis was that combining features of
Yan7874 (the activation attribute), features of the major classes
of orexin receptor antagonists (the binding attribute), and
information on the binding site would lead to such a model (see
chapter 4.1.1).
The best-performing pharmacophore model was built on the
docking pose of Yan7874, and it consisted of four features: a
hydrogen bond donor (HBD), two aromatic features (R1 and
R2), and a hydrophobic feature (H); these features form a
triangle with side lengths of 5.6 Å (HBD R2), 7.6 Å (R2 H), and
9.4 Å (H HBD) in three-dimensional space (Figure 15A).
Additionally, exclusion volumes were added to the model based
on the closest amino acid residues of the utilized docking
complex. The model discriminated the test set antagonists from
the decoys with 59% sensitivity (96/162 true positives) and 90%
specificity (37/41 true negatives), while the area under the
receiving operator curve (AUC) was 0.85.
Retrospectively, this pharmacophore model characterises
not only Yan7874 but also Nag26; the secondary sulphonamide
nitrogen of Nag26 maps on the HBD, the A-ring, and its
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aromatic substituent on R1 and R2, and the 3-methyl
substituent of the B-ring on H (Figure 15B). Interestingly, the
secondary sulphonamide has been reported to be crucial for the
activity of Nag26, as well as the presence of the rings A and B.
Additionally, altering the substituents of these rings has a
notable influence on the activity of these compounds—for
example changing the B-ring substituent from 3-methyl to 4-
methoxy drops the EC50 of the resulting compound
approximately 45-fold.165
Figure 15. A. Yan7874 mapped on the pharmacophore of publication I. B.
Nag26 mapped on the same pharmacophore. Hydrogen bond donor:
magenta, aromatic feature, brown; hydrophobic feature, cyan, carbon, grey;
nitrogen, blue; oxygen, red; sulphur, yellow; chlorine, green. The exclusion
volumes are not shown for clarity.
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5.2 VERIFYING THE ACTIVITY OF YAN7874
(PUBLICATION II)
To utilize Yan7874 in pharmacophore modelling, its agonist
activity required verification. First, we assessed the Ca2+
responses and PLC activation of Yan7874 in OX1 and OX2-
expressing cells and control CHO cells (see chapter 4.2).
Yan7874 induced strong and concentration-dependent Ca2+
elevation, and a rather small, but concentration-dependent PLC
response. When tested in the presence of orexin receptor
antagonist TCS-1102, Gq inhibitor UBO-QIC, or in control cells,
approximately 30–40% of these responses were shown to be
orexin receptor-mediated (Figure 16; see also 4.2.2 and 4.2.4).
Thus, in absence of a potent non-peptide orexin receptor
agonist with full efficacy, Yan7874 was a reasonable starting
point for pharmacophore modelling.
Figure 16. A. Concentration-response curves for orexin-A and Yan7874
responses in CHO-hOX2 cells, and control CHO cells [‘Yan 7874 (ctrl cells)’].
The responses are normalized to the response to 100 M ATP to allow
comparison of the Yan7874 responses in orexin receptor-expressing and
non-expressing cells. Yan7874 responses are shown as such [‘Yan 7874 (–
TCS 1102)’], in the presence of 10 M TCS-1102 [‘Yan 7874 (+ TCS 1102)’],
and as a subtraction of the latter from the former [‘Yan 7874 (specific)’]. B.
Orexin-A and Yan7874 concentration-response curves in OX2-expressing
cells normalized to the maximum response as determined by curve-fitting.
The responses were normalized to the orexin-A response (100%) separately
for each independent sample before averaging. n = 6.
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To characterize Yan7874 further, we assessed its Gs and Gi
protein coupling by AC activation and inhibition measurements,
respectively (chapter 4.2.5). Yan7874 did not couple either Gs or
Gi, but caused a response mimicking mitochondrial uncoupling
(an apparent increase in the AC activity, which was associated
with a decrease in cellular ATP+ADP counts and an actual
decrease in cellular cAMP). This suggested that Yan7874 may be
cytotoxic. Thus cell growth and viability in response to Yan7874
exposure was assessed, both by visual means and quantitatively
(see chapter 4.2.6). The morphological changes and the rapidity
of the appearance of the toxic effects, together with the apparent
decrease in the ATP levels, suggested necrotic cell death.
However, the cell death driven by Yan7874 is not linked to
orexin receptors, as it is equally as prominent in control cells
and lacks the hallmarks of orexin receptor-mediated cell death
in CHO cells (see chapter 2.3.3).
As Yan7874 drives cell death at a similar concentration range
as orexin receptor activation, its usefulness as a research tool is
rather limited. Also, Yan7874-mediated cell death is not
mediated via orexin receptors, and thus could not be
considered, for example, for development of cancer treatments.
5.3 DISCOVERY OF NOVEL OREXIN RECEPTOR
MODULATORS (PUBLICATIONS I, III AND IV)
Two virtual screening campaigns were conducted to find novel
orexin receptor ligands: in publication I, the pharmacophore
model described in chapter 5.1 was used as a virtual screening
filter, whereas in publication III a docking-based virtual
screening was conducted on the crystal structure of OX2
receptor (PDB ID: 4S0V). Both these virtual screening methods
are described in detail in chapter 4.1. and the subsequent
pharmacological screening in chapter 4.2.2. The screenings led
to identification of orexin receptor antagonists, weak agonists,
and compounds potentiating the actions of orexin-A.
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5.3.1 ANTAGONISTS
In publication I we identified 21 compounds that produced over
50% inhibition of [125I]-orexin-A, and the seven best were
selected for Ki evaluation (I-8–14 in Table 3 and Figure 17). In
contrast, in publication III, 12 compounds inhibited [125I]-
orexin-A binding over 30%, and Ki’s were assessed for the two
most promising (III-22 and III-32, Table 3 and Figure 17). All of
these ligands displayed at least single-digit micromolar Ki
values, the best, I-8 and I-10, reaching a nanomolar range.
Azulene (as in compounds III-22 and III-32) is an
unexplored scaffold in medicinal chemistry, and only a few
reports of azulene-based compounds are found in the scientific
literature.218–221 Thus, the novelty of the azulene compounds
III-22 and III-32 as orexin receptor antagonists is evident.
However, compounds I-8–14 are from a screening library
comprising commercially available compounds, and thus some
of the found ligands might resemble already known orexin
receptor antagonists. The novelty of the ligands in publication I
was studied using principal component analysis (PCA); I-11 and
I-14 were structurally most distinct from the previously
reported orexin receptor antagonists. The closest compound,
instead, was I-8, which shows clear similarities to 2-SORAs
(Figure 9). Even though the structure of I-8 combines different
chemical scaffolds found from these antagonists, it has not been
reported previously as an orexin receptor ligand.
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Figure 17. Antagonists identified in publications I and III.
Table 3. The Ki values of these antagonists assessed either in competition
















I-8 6.3 ± 1.2 46.7 ± 40.3 0.1 ± 0.06 0.1 ± 0.05
I-9 1.1 ± 1.0 16.2 ± 10.5 0.4 ± 0.2 11.0 ± 6.0
I-10 1.2 ± 0.1 6.0 ± 3.6 0.2 ± 0.09 0.3 ± 0.2
I-11 0.8 ± 0.2 7.0 ± 3.6 1.1 ± 0.5 1.0 ± 0.8
I-12 2.7 ± 1.6 10.3 ± 4.6 1.3 ± 0.8 1.7 ± 1.2
I-13 12.0 ± 4.4 21.6 ± 14.7 1.0 ± 0.5 1.2 ± 0.9
I-14 6.7 ± 2.4 13.1 ± 3.6 0.8 ± 0.2 0.9 ± 0.4
III-22 n.d 4.8 ± 1.8 n.d 3.6 ± 1.1
III-32 n.d 7.6 ± 2.0 n.d 8.6 ± 2.8
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The Ki values of compounds I-8–14 were assessed both in the
competition binding and Ca2+ elevation assays (Table 3). On
OX2 receptors these two methods lead generally to a similar
outcome (with the exception of I-9), while on OX1 the functional
Ki values of compounds I-8–12 were notably higher than their
binding assay-assessed counterparts. The reason for this is
unknown, but the binding kinetics have been reported to have a
role in such difference.194 However, in the report of Mould et al.
the functional Ki’s were better than those from the competition
binding assay, and not the reverse as in the data presented here.
For compound I-9, the functional Ki values were similarly
increased for both receptor subtypes, which may be due to
compound-induced absorbance.
5.3.2 AGONISTS
5.3.2.1 Identified non-peptide orexin receptor agonists
Together with the antagonists of publications I and III,
compounds with weak orexin receptor agonist activity were
identified (Figure 18), and some of these compounds and their
analogues were studied further in publication IV. In publication
I, pharmacological screening gave rise to a set of 18 compounds,
which could be potential orexin receptor agonists (i.e. they gave
a signal in Ca2+ elevation assay, see Figure 14). Furthermore, the
responses to six of these compounds were validated to be orexin
receptor-mediated, and five had Ki values in the micromolar
range. Two compounds are not currently disclosed, and thus
their structures are not shown in Figure 18. Apart from these,
the azulene studies (publications III and IV) led to a set of five
compounds with orexin receptor-mediated agonist activity.
Results and discussion
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Figure 18. A. Agonistic hits of publications I, III, and IV. B and C. Total and
specific Ca2+ responses of these hits at 10 μM (B), and 10 μM and 32 μM (C)
compound concentration. Orexin-receptor-mediated responses were
assessed by blockade with known antagonists (B) or in control CHO cells
(C). The responses were normalized to the Emax of orexin-A separately
before averaging. n = 3 6.
The agonist activities of these compounds are weak; at the
highest concentration utilized, 10 μM in publications I and III
(except III-19 a.k.a IV-37), and 32 μM in publication IV, the
orexin-receptor-mediated fraction of their Ca2+ responses are
approximately 5–10% of Emax of orexin-A on either one or both
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receptor subtypes (Figure 18B and C). The orexin-receptor-
mediated responses to azulene compounds seemed
concentration-dependent (publication IV), however the
solubility of these compounds unfortunately prevented full
saturation. Unlike the other compounds, IV-26 was more active
at 18 μM than at 32 μM concentration—at 18 μM concentration
the orexin receptor-mediated activities were 7.4 ± 1.9% and 5.4
± 1.5% of Emax of orexin-A on OX1 and OX2, respectively
(publication IV).
Interestingly, compound III-19 did not show any Ca2+
response at 10 μM concentration, but at 32 μM an orexin-
receptor-mediated response of approximately 10% on OX1
(Figure 18), and at 45 μM approximately 20% on both receptor
subtypes was detected (publication IV). This response is almost
of a similar magnitude to the maximum response to Yan7874
(Figure 16), however the III-19 concentration required for the
response is somewhat 4-fold higher than that of Yan7874.
Additionally, also III-19 had Ki values at the micromolar level
(Figure 18A).
5.3.2.2 Insights into orexin receptor activation
Even though the identified agonists are weak, their structural
diversity offers new insights into orexin receptor activation. The
only known non-peptide orexin-receptor agonist with full
efficacy is Nag26, and although the structural optimization of it
led to a set of compounds with weaker orexin-receptor-agonist
activities, they are structurally really similar to each other (only
small alterations of A- and B-ring substituents are reported in
165). Thus, deriving a bigger picture of the molecular features




Figure 19. A. A pharmacophore describing the active ligands and the B ring
fraction of Nag26 (cobalt blue). B. Active ligands (grey sticks) and Nag26
superimposed by the pharmacophore. Hydrogen bond acceptor: green,
aromatic feature: brown, hydrophobic feature: cyan, nitrogen: blue, oxygen:
red, sulphur: yellow, fluorine: light blue.
When studying the structures of the agonistic hit
compounds, some similarities are evident; all of the compounds
seem to have a (semi)aromatic core structure, polar linker
regions, and aromatic group(s) in the far ends (Figure 18A).
Additionally, at least one of these aromatic groups has a polar
functionality. When these similarities were rationalized to a
pharmacophore, it not only mapped all the active azulenes and
compounds I-4 and I-7, but also the B-ring end of Nag26 (Figure
19). In the structure of Yan7874, instead, there is a chlorine
atom mapping on top of one of the acceptor features, and thus
it is not retrieved by the pharmacophore. However, the electron
cloud of chlorine is capable of forming a halogen bond with
hydrogen-bond donors, and thus the pharmacophore could be
concluded to describe also Yan7874. This pharmacophore does
thus represent 9/11 active ligands, and additionally, it rules out
35/42 inactive compounds (see publication IV).
Interestingly, the similar pharmacophoric features
represented in Figure 19 can be mapped also on the A-ring end
of Nag26. When done so, I-4, I-5, I-7, III-19, IV-26, and IV-28
are retrieved (i.e. 8/11 actives, if including Yan7874), and 33/42
inactive azulene compounds are ruled out. The azulene-based
hits are especially small compounds barely reaching both ends
of the described pharmacophores, a Nag26 molecule could
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actually be mimicked by two of them, for example by overlaying
one IV-28 molecule on the A-ring and another IV-28 molecule
on the B-ring of Nag26.
Apart from pharmacophoric representations, we studied the
agonist compounds by molecular docking (Figure 20;
publication I; see also retrospective docking in chapter 4.1.2).
When docked to the OX2 crystal structure, all binding poses of
the studied agonists overlap partially with that of the co-
crystallized suvorexant (Figure 20). Compared to suvorexant,
Nag26 presents an extended binding mode reaching towards a
pocket between TM5 and TM6 (A-ring), and TM6 and TM7
(above the binding site of suvorexant; B-ring; Figure 20B).
Yan7874 and III-19 also reach towards TM5 and TM6, but as
much smaller molecules than Nag26 they do not extend towards
the TM6–TM7 pocket (Figure 20C and D). Apart from the
representative poses selected by the Glide gscore, however, both
of these smaller ligands also show binding modes, wherein they
have flipped around their vertical axes, or reach towards the
TM6–TM7 pocket and not that between TM5 and TM6
All the representative poses of the agonist ligands can form
a hydrogen bond with Gln3.32 (sulphonamide oxygen of Nag26,
hydroxyl group of Yan7874, and carbonyl group of III-19). It is
noteworthy that the sulphonamide group of Nag26 docks
approximately to the same location in the binding site than that
of EMPA in the OX2 crystal structure (one of the sulphonamide
oxygens is within 4.0 Å distance from Thr3.33). However, the
other sulphonamide oxygen of Nag26 is interacting with Gln3.32,
while that of EMPA interacts with Gln4.60. According to
Nagahara et al., the secondary sulphonamide is crucial for the
agonist activity of Nag26—in the structure of 2-SORA EMPA the
sulphonamide is tertiary, and its conformational space is thus
more restrained than that of Nag26. The secondary
sulphonamide allows the Nag26 molecule to adopt the bent
conformation observed in the docking studies (publication I and
165,166); also the inactivity of the corresponding amide derivative
of Nag26 suggests the importance of the bent conformation.165
Additionally, the secondary sulphonamide nitrogen might be
Results and discussion
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important for not only allowing but also stabilizing the bent
conformation of Nag26, for example via water-mediated
intramolecular hydrogen bonds with the methoxy-oxygen of the
A-ring or a carbonyl oxygen of the B-ring region of the
compound.
Figure 20. A. Suvorexant in complex with OX2. B–D. Docking poses of Nag26
(B), Yan7874 (C), and III-19 (D). View from TM6, colour code as in Figure
12. The binding site water molecules are not shown for clarity.
The docking pose of Nag26 also forms a hydrogen bond with
His7.39, which flips the His7.39 side chain away from Asp2.65
breaking a salt bridge between TM2 and TM7. Yan7874 and III-
19 could also interact with His7.39 (aromatic  interaction).
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The tight interactions between the agonist ligands of 2-
adrenoceptor and amino acid residues 3.32 and 7.39 are
commonly observed in the corresponding crystal structures
(chapter 2.1.3). Apart from these, Yan7874 can form hydrogen
bonds with Thr3.33 (hydroxyl group) and Gln4.60 (primary
amine), whereas III-19 can hydrogen bond with His5.39
(carboxyl group). The Thr3.33 interaction tightens the contact
with TM3, and also might explain the slight OX2 selectivity of
Yan7874. In the antagonist-bound structure, His5.39 forms a salt
bridge with Gluxl2.52 (of the -hairpin), and interacting with
His5.39 could disturb that contact. These ligands can also interact
with Tyr6.48 (aromatic  interaction), which is located in one
of the suggested microswitch motifs of GPCR activation (Table
1).
Nag26, Yan7874, and III-19 could also interact with Ser6.52,
by a hydrogen bond (Nag26), a halogen bond (Yan7874), or an
electron-deficient edge of the benzoyl group (III-19). Nag26
interacts with Ser6.52 by its amide carbonyl functionality at the
A-ring-end of the compound. The A-ring analogues of Nag26 (in
Table 1 of 165) highlight the importance of the amide carbonyl
functionality in that region; amine- or methoxy-substituted
phenyl groups, as well as non-substituted phenyl group as
A-ring substituents led to a notable drop in both EC50 and Emax.
If the TM5 would move slightly towards the binding site, as
is suggested to happen upon activation of many GPCRs, Thr5.46
would also be within reach to interact with these ligands (similar
interactions as with Ser6.52). Interaction with an amino acid in
position 5.46 is observed in the crystal structures of 2 agonists.
Angiotensin receptors also demonstrate the importance of the
pocket between TM5 and TM6. Olmesartan, an inverse agonist
of angiotensin receptors, can be converted into an agonist by
growing the ligand (Figure 21A; reviewed in 11). Interestingly,
the crystal structure of olmesartan in complex with AT2
indicates that the added phenyl group would indeed reach
towards the TM5–TM6 pocket (Figure 21A–C).222
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Figure 21. A. AT1 receptor ligands presented as in 11. B. OX2 in complex with
suvorexant (cobalt blue). C. AT2 in complex with olmesartan (orange). D. A
zoom-out of OX2–suvorexant (cobalt blue) complex. E. ETB in complex with
endothelin 1 (rose). Receptors are shown as grey cartoon; cartoon between
positions 6.50–7.39 (B and C) and 6.48–7.39 (D and E) is hidden for clarity.
Blue is nitrogen, red is oxygen, and green is chlorine. View as in Figure 12.
Apart from 2 and angiotensin receptor agonists, endothelin
1 (ET1; a peptide agonist) in complex with ETB receptor also
reaches towards TM5 and TM6 (Figure 21D and E) and interacts
with amino acids in positions 3.32, 3.33, and 7.39. Interestingly,
the C-terminus of ET1 is non-helical, both in solution and when
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binding to its cognate receptor.37,223 Even though the C-
terminals of orexin peptides are helical in solution, it is possible
that they could also bind in such an extended conformation.
Additionally, the ET1–ETB provides insights into the
interactions involving the -hairpin and N-terminus of the
receptor; the helical part of the peptide-ligand sandwiches
between these two regions (Figure 21E). As both N-terminal
helix and the -hairpin region of orexin receptors have been
shown to be important for the binding/recognition of orexin-A,
it is highly possible that these regions sandwich orexin-A the
same way. Additionally, the TM6–TM7 pocket corresponding to
the one above the binding site of suvorexant is occupied by the
side chains of the helical part of ET1, and it could be possible
that a ligand (e.g. Nag26) occupying this pocked would interact
with the N-terminus of the receptor as ET1 does.
Altogether, these findings suggest the importance of three
regions in the orexin receptor binding site in terms of receptor
activation: (1) the ‘antagonist binding site’, and interactions
between the ligand, TM3 and TM7, (2) the TM5–TM6 region,
wherein the interaction network would be tightened by the
inward movement of TM5, and (3) the TM6–TM7 region,
approximately one helical turn upward from His7.39, and with a
possible interaction with the N-terminal helix of the receptor.
Of the orexin receptor agonists discussed here, only Nag26 can
occupy all these regions simultaneously.
5.3.3 COMPOUNDS POTENTIATING THE ACTIONS OF
OREXIN-A
In general, GPCR agonists and antagonists can be structurally
similar to each other (reviewed in 11), and thus it felt only
reasonable that finding one of these ligand types among
structurally similar compounds lead to finding of the other.
However, it was a bit unexpected to also identify compounds,
which potentiated the actions of orexin-A (both binding and the
functional Ca2+ response), as such ligands are typically
considered to bind to another, allosteric, binding site (reviewed
Results and discussion
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in 14). In Rhodopsin family GPCRs these allosteric sites can be
in close proximity to the orthosteric binding sites though, and,
for example, in CCR5 chemokine receptor (CCR5) and M2, the
allosteric ligands are binding just above the orthosteric pocket
(i.e. the TM6–TM7 region discussed above; reviewed in 224).
Additionally, the only previously reported series of orexin
receptor potentiators was also found while screening for orexin
receptor antagonists.199
Figure 22. The effects of three most promising OX1 receptor potentiators on
the Ca2+ responses elicited by 0.02–0.03 nM orexin-A and 60 nM ATP
(corresponding to the EC20 of each ligand; publication III). The responses
were separately normalized to the control orexin-A or ATP responses,
respectively, for each independent experiment before averaging. The
significances were calculated as compared with the corresponding control.
ns (not significant) P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001; n = 3 4.
In publication III we identified a set of 12 compounds, which
potentiated the binding of [125I]-orexin-A in the competition
binding assay. Of these, two compounds acted as weak agonists,
which could lead to such a phenomenon (via e.g. receptor
dimers, see below), however, the effects of the other ten could
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not be explained. When studied further in the Ca2+ elevation
assay, all these compounds, except III-19 (which was shown
later to be an orexin receptor agonist at higher concentrations),
potentiated the response to orexin-A, and eight of them did not
trigger measurable Ca2+ elevation on their own. The most
effective potentiators, III-11, III-17, and III-28 potentiated the
Ca2+ response to a small, sub-EC50, concentration of orexin-A
approximately two-fold on OX1 receptors (Figure 22).
Additionally, none of them potentiated the effects of ATP, when
studied similarly to orexin-A potentiation, indicating that the
observed potentiation was orexin receptor-mediated.
To determine whether the azulene-scaffold had a crucial role
to the observed potentiation effect, we studied also a set of
indole-scaffolded compounds (publication IV). Interestingly,
these indole analogues highlighted the importance of the
location of the ester functionality in respect of the
methoxybenzoyl moiety; the more linear IV-31 and IV-34 over-
performed their bent counterparts. However, the tri-substituted
indoles representing III-11 showed the most promising activity
(approximately 1.7-fold).
In general, potentiating the actions of an endogenous ligand
is a rather complex phenomenon, and currently it is not fully
understood. In addition to the allosteric modulators discussed
above (binding either to the nearby or distinct allosteric binding
sites), the possible effectors are acting directly via receptor
dimerization/oligomerization, and indirect effects affecting the
orexin-A binding and the downstream signalling machinery
(e.g. via Ca2+ levels, see 2.3.1.4).
In case of potentiating the actions of orexin-A, a few
enlightening pieces of information are available. First, at low
concentrations orexin-A displays self-potentiation (positive
cooperativity) in the competition binding assay,97 and a similar
phenomenon was also evident with the agonist ligands (e.g.  I-7
and III-7). Considering that the orexin-A peptide occupies a
single site at each receptor, the self-potentiation of orexin-A
binding most likely occurs through receptor dimers or
oligomers, which orexin receptors have shown to form at least
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in expression systems (chapter 2.3.2). Noteworthy, acting via
receptor dimers would mean that also the small molecular
potentiators bind to the orthosteric binding site (reviewed e.g.
in 14).
Secondly, extracellular Ca2+ levels affect the binding of
orexin-A possibly via an allosteric Ca2+ binding site (see chapter
2.3.1.4). There is reported to be an allosteric Na+ binding site in
most of the Rhodopsin family GPCRs, however, OX2 receptors
have been shown to lack this (chapter 2.2.3). Additionally,
molecular modelling of the OX1–orexin-A complex198 suggests
that the His26 of orexin-A clusters close to His7.39 and Asp2.65,
which is rather interesting, as histidine/aspartic acid clusters
are known to participate in the hexahedral coordination of
metal ions. However, the Ca2+ elevation to cytosol, caused by the
agonistic ligands, cannot affect the orexin-A binding if efflux
does not occur, so possibly the binding effect of extracellular
Ca2+ is not the phenomenon dealt with here.
Thirdly, intracellular Ca2+ levels affect the downstream
signalling effects, possibly by complexation with the receptor-
G protein complex (chapter 2.3.1.4). This leads to potentiation
of the detected functional responses to orexin-A (such as those
mediated by PLC and AC pathways). Potentiated PLC activation
affects the Ca2+ response detected in our assay, and represents
the least interesting type of potentiation in light of the
compounds tested (as it is not targeting orexin receptors). To
rule out the effect of intracellular Ca2+, we employed ATP
controls, which mimicked the Ca2+ elevation of the tested
ligands (10 nM ATP in case of compounds not triggering Ca2+
elevation, Figure 22). Thus, it is liable that the compounds
potentiating the Ca2+ response to orexin-A significantly more
than the ATP control, are acting via orexin receptors.
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6 CONCLUSIONS AND FUTURE
DIRECTIONS
This investigation demonstrates that molecular modelling can
be utilized in finding novel ligands, also in circumstances where
the amount of background knowledge is rather modest. With
computer-aided methods, we succeeded to rationalise the
orexin receptor binding and activation attributes and construct
a pharmacophore model, which led to the identification of novel
orexin receptor ligands, both antagonists with binding affinities
at 0.1–1 μM range and weak agonists; the corresponding hit
rates were 1.7% and 1.5%, respectively. Additionally, 30/395 of
the pharmacophore-based virtual screening hits inhibited
[125I]-orexin-A binding over 30% giving an overall hit rate of
7.6% for orexin receptor ligands. This demonstrates the power
of the integrated screening procedure, even though the lack of
precise data of the hit rates of HTS campaigns prevents a fair
comparison.
The insights into orexin receptor activation provided by
these compounds aided the identification of a novel set of
azulene-based orexin receptor agonists with concentration-
dependent activities and accessibility to further modifications
by in-house chemistry. Additionally, novel antagonists and
orexin receptor potentiators were identified. For the azulene
screening, the hit rates were even higher: 39% for antagonists
(over 30% inhibition of [125I]-orexin-A binding), 19% for
potentiators, and 9.7% for agonists leading to approximately
68% hit rate for orexin receptor ligands. Even though the
number sounds high, it is in line with the reported hit rates of
virtual screenings for other GPCR ligands, such as those
targeting 2,  A2A, and CXCR4, as well as H1 histamine and D3
dopamine receptors (20–70% hit rates; reviewed in 32). It
should be noted, though, that hit rates can be defined using
different success criteria, which heavily affect the final numbers.
In the future, much remains to be understood regarding
orexin receptor activation, as well as the potentiation of the
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actions of orexin-A. From the computational
chemistry/molecular modelling point of view, one missing link
is all-atom molecular dynamic simulations with full receptor
structures and agonist ligands (Nag26, orexin-A, orexin-B) to
provide insights into conformational changes occurring during
orexin receptor activation. Additionally, as crystal structures of
active GPCRs are available, homology modelling could be
utilized to build a model of an active orexin receptor
conformation, which would then be a target for molecular
docking or MD studies.
From the medicinal chemistry/compound design point of
view, the next step would be testing the pharmacophore
hypothesis of two small ligands mimicking the features of
Nag26 by studying di-azulene-scaffolded compounds, e.g. by
bridging some of the current hits. The two undisclosed agonist
hits from publication I should also undergo structural
optimization. From the molecular biology angle, instead, the
orexin receptor point mutations in regions suggested important
for Nag26-mediated orexin receptor activation (TM5–TM6 and
upper TM6–TM7 pockets) would indeed be interesting. These
point mutations, especially in the TM6–TM7 region could also
provide insights into the action of the identified potentiators.
Finally, understanding the pharmacology of the orexin receptor
activation and potentiation, and especially the effects of
receptor dimerization/oligomerization, would be particularly
helpful. Utilizing radiolabelled antagonist, such as
[3H]-almorexant instead of [125I]-orexin-A, in the competition
binding assay would possibly aid the understanding the
potentiation effect mediated by our compounds.
The field of orexin research has evolved dramatically during
the time frame of these studies, and knowledge of orexin
receptor binding and activation has similarly expanded.
Especially the solved orexin receptor crystal structures and
identification of Nag26 have opened new possibilities, not only
in computational drug discovery but also in understanding the
phenomenon at hand. With such an accelerating trend, it feels
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indeed possible that one day the field reaches the understanding
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